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Non-human primates are often used in the development and testing of vaccines and 
therapeutics for malaria.  Infection of rhesus macaques (Macaca mulatta) with Plasmodium 
coatneyi causes cerebral malaria (CM) at high levels of parasitemia.  To prevent mortality, 
parasitemia is frequently treated prior to this point when cerebral signs are largely absent.  The 
public health significance was to determine the validity of this as a model for studying malarial 
anemia (MA) by examining hematological profiles, cytokines, and effector molecules shown to 
be important in childhood MA, including tumor necrosis factor (TNF)-α, interleukin (IL)-10, 
(IL)-12p40, and interferon (IFN)-γ, and nitric oxide (NO) at eight different time points during the 
acute infection.  Peripheral parasitemia was monitored daily throughout infection.  Venepuncture 
was performed for hematology panels on days 0, 2, 5, 7, 8, (peak parasitemia), 10, 15, 22, 34, 42, 
56, and 150 post-infection (PI) for monitoring acute and chronic malaria infection.  Complete 
blood counts (CBC) revealed that monocytes (MO) were highest during the initial rise in 
parasitemia, neutrophils (NEU) were highest at peak parasitemia, and lymphocytes (LY) 
remained constant throughout infection, except at peak parasitemia where levels were 
dramatically reduced.  Platelets (PLT) declined shortly after infection and decreased until day 15, 
where levels sharply increased to higher than baseline values on day 19 PI.  Hemoglobin (Hb) 
was lowest at parasite clearance (day 15 PI).  Elevated peripheral blood mononuclear cell 
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(PBMC) transcripts (determined by real time RT-PCR in circulating blood mononuclear cells) 
and plasma levels (determined by ELISA) were associated with enhanced disease severity (peak 
parasitemia, thrombocytopenia and anemia).  Plasma cytokine levels were not correlated with 
PBMC transcript levels, suggesting that the plasma cytokine levels may be from multiple cellular 
sources in addition to PBMC.  Low IL-10 relative to TNF-α (IL-10/TNF-α plasma ratio) 
coincided with the lowest Hb concentration, a finding we have shown in children with MA. 
Taken together, these results demonstrate similar patterns of cytokine and effector molecule 
dysregulation in rhesus macaques infected P. coatneyi as that observed in humans with P. 
falciparum-induced malarial anemia.  
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1.0  INTRODUCTION 
1.1 PURPOSE 
Malaria is a global health threat with an estimated 300-500 million new infections and 
1.5-2.7 million deaths attributed to this disease annually (1, 2).  As drug resistance continues to 
be a problem and with no available vaccination, it is critical to gain a further understanding of 
the molecular mechanisms and immune regulation of malaria.  Developing appropriate model 
systems is essential for investigating the molecular immunological basis of the disease for use in 
vaccine and pharmacologic trials.  Non-human primates, such as rhesus macaques (Macaca 
mulatta) infected with a species-specific malaria strain (Plasmodium coatneyi), have been shown 
to be a useful model system for studying CM. (3),(4), and have also been shown as a valid model 
of malaria in pregnancy (5) Several other model systems exist to study malaria, but the species 
are not as closely related to humans and differ in response to malaria including murine/P. 
berghei (6) and Aotus/P. falciparum models (7),(8). 
In human infections with malaria, we know that the interactions between pro (Th-1) and 
anti-inflammatory (Th-2) cytokines play a critical role in the immunopathogenesis of malaria (9), 
(10).  Pro-inflammatory cytokines are released primarily by leukocytes in response to numerous 
different factors during a malaria infection, and have some similar functions to the cells that 
produce them.  In this project, we are examining the immune modulation from a hematological 
perspective on the role of cytokine and effector molecules in rhesus macaques during an 
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infection with Plasmodium coatneyi to determine if this could be a suitable model system for 
examining malarial anemia. 
1.2 MALARIA 
1.2.1 Global Impact 
Malaria exists in 100 countries but is mainly confined to developing tropical areas of 
Africa, Asia and Latin America.  There are over 300 million of people affected by malaria world-
wide each year, resulting in more than a million deaths (1).  Around 90% of these deaths occur in 
Africa, with children less than five years of age bearing the largest death burden of malaria, due 
mostly to their non-immune state (2).  Plasmodium falciparum (in humans) is the main cause of 
severe clinical malaria and death.   It is estimated that over 50% of the world’s population is at 
risk for malaria, which is a 10% increase in the past ten years (2). 
The distribution of malaria is solely dependent upon the occurrence of the Anopheles 
mosquito, as it is the only species capable of serving as the host for the Plasmodium parasite 
(Figure 1). Of the four species of Plasmodium that infect humans, P. falciparum is most 
widespread, and causes the most severe malaria.  Falciparum malaria is also found in areas of 
Asia and South America, though P. vivax malaria is more common. One reason why an 
overwhelming proportion of the malaria burden exists in Africa is that many countries lack the 
infrastructure and resources necessary to mount a sustainable campaign against malaria, and as a 
result, very few African countries have benefited from historical efforts to eradicate malaria.  In 
Africa, malaria accounts for 40% of public health expenditure, 30-50% of inpatient hospital 
admissions, and up to 50% of outpatient hospital visits in areas with high malaria transmission 
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(1).  Malaria is most prevalent in developing areas of the world (58% of cases).  This 
complicates matters in that these patients have the least access to good health care and have 
economic struggles that are only exacerbated by the burden of malaria (2). 
Figure 1
BURDEN OF MALARIA
 
Figure 1: Global Burden of Malaria 
 
1.2.2 Plasmodium Life Cycle 
Four species (P. vivax, P. ovale, P. malariae, and P. falciparum) in the Plasmodium 
genus of protozoa within the subfamily of Haemosporidia infect humans.  Malaria is a complex 
disease caused by the single-celled Plasmodium blood parasite. The parasite’s life cycle is split 
between the vertebrate host and the insect vector, the Anopholes mosquito (Figure 2).  The 
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mosquito becomes infected when it takes a blood meal containing Plasmodium gametocytes, 
which pass into the salivary glands of the mosquito and travel to the gut, where they reproduce 
sexually and develop into sporozoites. Unlike the human host, the mosquito host does not suffer 
noticeably from the presence of Plasmodium parasites. 
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Figure 2: Plasmodium Life Cycle 
 
Two stages of the Plasmodium life cycle exist in the human host: the exo-erythrocytic 
and erythrocytic cycle.  The exo-erythrocytic cycle occurs when the Anopholes mosquito injects 
its saliva and Plasmodium sporozoites into tiny blood vessels of the human host during a blood 
meal.  The sporozoites travel through the bloodstream to the liver, where the parasite enters the 
liver cells. The co-receptor on sporozoites involves thrombospondin domains on 
circumsporozoite protein and thrombospondin related adhesive protein (TRAP), which 
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specifically bind the heparin sulfate proteoglycans on hepatocytes (11).  In the liver, the 
sporozoites divide (tachysporozoites) and mature into thousands of merozoites in period of 9-16 
days (12).  The distended liver cell bursts open and releases the merozoites into the blood stream. 
The parasite can only survive if it rapidly attaches to and enters the host RBCs.  In order to enter 
the RBC, the parasite must engage the receptor, undergo apical re-orientation, junction formation 
and signaling.  It is not certain which merozoite surface signal recognizes the RBC surface 
signal.  When the merozoite enters the RBC, the erythrocytic cycle begins.  Once inside the 
RBC, the parasite matures and divides, going from merozoite, to trophozoite and then schizont 
stage, forming up to 32 daughter merozoites. 
Disease begins when the asexual parasite multiplies within the RBC. After expansion of 
the parasite, the RBC bursts, releasing merozoites to invade other erythrocytes.  This exponential 
growth and destruction of RBCs contributes to the anemia associated with P. falciparum-malaria.  
Within the erythrocytes, merozoites can also differentiate into male and female gametocytes, 
which are released upon rupture of parasitized RBCs (pRBC).  During a blood meal of the 
infected human host, the mosquito ingests gametes which fuse to form a diploid zygote.  The 
zygote develops into an oocyst, within which sporozoites are produced and then transmitted to 
the human host during the mosquito’s subsequent blood meals (12).   
1.2.3 Pathophysiology 
 The release of merozoites into the bloodstream gives rise to symptoms that include fever, 
shivering, joint pain, headache, repeated vomiting, generalized convulsion, and coma.  
According to the World Health Organization (WHO) criteria of malaria, anemia (Hb < 5g/dl), 
renal failure (serum creatinine >3 mg/dl), pulmonary edema, hyperparasitemia (> 5% of 
 5 
erythrocytes infected), jaundice, circulatory collapse, and/or shock are all clinical signs of severe 
malaria (13).  The mortality from malaria comes from complications of the infection.  Cerebral 
manifestations can lead to coma and severe and refractory anemia.  This can lead to hypoxia and 
cardiac decompensation.  All of the typical clinical and severe disease pathology associated with 
malaria is caused by the asexual erythrocytic or blood stage parasites. 
1.2.3.1 Parasitic Products 
 
Hb is the oxygen-carrying protein in RBCs, made up of globin chains and heme.  The 
Plasmodium parasite feeds on Hb, but heme, which is released when the parasite digests Hb, is 
toxic to and lyses malaria parasites (14), (15), (16).  Complete removal of toxic molecules is 
achieved by the parasite by a process of biocrystallization.  In order to avoid the toxic effects of 
heme, the parasite incorporates the released heme into hemozoin (Hz), malarial pigment, which 
is an insoluble polymer of ferriprotoporphyrin (FP-IX). (17).  When the parasite develops in the 
erythrocyte, numerous known and unknown waste substances such as Hz and other toxic factors 
accumulate in the infected RBC.  These toxins are emptied into the bloodstream when the 
infected RBCs lyse and release invasive merozoites.   
Monocytes and macrophages phagocytose P. falciparum-derived Hz during a malaria 
infection by either the phagocytosis of pRBCs or Hz released after the RBC bursts (18).  The Hz 
and other toxic factors such as glucose phosphate isomerase (GPI) from merozoite surface 
proteins (MSP)-1, and -2, stimulate monocytes, macrophages and other cells to produce 
cytokines and soluble factors which act to produce fever, rigors and influence other severe 
pathophysiological features associated with malaria.  Previous studies indicate that Hz and 
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synthetic malarial pigment (β-hematin) cause up-regulation of TNF-α from human PBMC (19), 
(20), (21), (22). 
1.2.4 Immune Response 
1.2.4.1 Cytokine and Effector Molecule Regulation 
 
The cytokine response that leads to malaria is still not fully explained, nor is the role of 
cytokines at different stages of infection.  The severity of disease may vary depending upon the 
level and the type of cytokines produced after malaria parasite infection.  Cytokines can play 
both protective and pathogenic roles during malaria infection, and also mediate interactions 
between humoral and cellular immune responses (23).  Cytokine release is triggered by Hz (24), 
merozoites, rupture of parasitized RBCs, and by parasite antigens, such as the GPI anchor on 
plasmodial antigen (25). 
 Production of pro-inflammatory cytokines by phagocytic cells is a hallmark of malaria 
infection (Figure 3).  This type 1-biased immune response to P. falciparum infection is 
culminated primarily by the release of TNF-α and IFN-γ which directly or indirectly contribute 
to parasite killing through activation of phagocytosis or NO dependent pathways.  In addition, 
the pro-inflammatory response to infection is often a precursor to severe clinical sequelae during 
malaria pathogenesis (26).  Protective immunity in malaria is coordinated by the release of 
pro-inflammatory cytokines such as IL-12, TNF-α, and IFN-γ (27).  IL-12, released from 
primarily monocyte-macrophages, initiates the inflammatory cascade through the activation of 
cytotoxic and natural killer cells (28).  Acute falciparum-malaria induces suppression of IL-12 
that is associated with leukocyte ingestion of Hz and disequilibrium in the balance of IL-12, 
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TNF-α, and IL-10 (29), (30).  IL-12 induced protection in malaria is related to the ability of IL-
12 to promote secretion of IFN-γ from Th1 cells (31), (32), (33).  IL-12 has been suggested to 
stimulate erythropoiesis through the induction of IFN-γ production (34).  Elevated IL-12 levels 
have been shown to be inversely correlated with parasitemia, which may be related to the 
impaired function of monocytes due to acquisition of Hz.  Non-immune African children with 
severe malaria have been shown to have reduced levels of IL-12 relative to those with mild 
malaria, and high levels of TNF-α and IL-10 (29). 
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Figure 3: Proposed Model of Cytokine and Effector Molecule Dysregulation during Malarial Anemia 
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 IL-12 stimulates the release of pro-inflammatory IFN-γ from CD4+ T cells.  IFN-γ activates 
macrophages to increase phagocytosis and cytotoxicity, aiding in parasite killing and clearance.  
High serum levels of IFN-γ have been shown in malaria-naïve adults to correlate with their first 
clinical episode of acute P. falciparum malaria (35) and with level of parasitemia (36).  Levels of 
IFN-γ are lower in humans who live in malaria endemic areas than those who are malaria-naïve 
and exposed for the first time (37).  IFN-γ has been shown to also increase in the 24 hour period 
before onset of fever and parasitemia (38).  It has been suggested that high levels of IFN-γ-
inducing macrophage activation may promote anemia (39).  IFN-γ upregulates cytoadherence 
ligand intercellular adhesion molecule (ICAM)-1, which leads to an increase in sequestration of 
the parasite (40).  Children with CM have lower levels of plasma IFN-γ relative to those with 
uncomplicated malaria, which implicates this cytokine to play a protective role in preventing 
disease severity and CM (41).  While the early acute release of IFN-γ may be protective, the 
sustained release of IFN-γ may be a factor in severe malarial anemia (SMA) (42), (43). 
During malaria, IFN-γ stimulates monocytes-macrophages to release TNF-α.  Over-
production of TNF-α is associated with promotion of anemia in a variety of chronic and acute 
inflammatory diseases (44), including anemia associated with rheumatoid arthritis (45).  Serum 
levels of TNF-α have been shown to be correlated with both parasitemia and disease severity and 
severe anemia (46), (47).  However, it is clear that TNF-α is not solely responsible for disease 
severity as high serum levels have also been found in P. vivax infections where severe disease is 
rare, suggesting that other factors also contribute to pathogenesis (48).  TNF-α is a pyrogen, 
know to cause fever in malaria.  Studies have shown that fever induced by TNF-α may 
substantially reduce the growth of erythrocytic forms of falciparum (49).  Overall these studies 
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suggest that low levels of TNF-α may be protective while overproduction of TNF-α is 
pathogenic during malaria infection. 
Anti-inflammatory IL-10 is produced by monocytes and T-cells in response to pro-
inflammatory cytokines.  B-1 cells require IL-10 for both proliferation and maturation.  In a 
recent study, B cell knock-out mice did not produce IL-10, but only presented a Th1 response, 
whereas normal mice presented first a Th1 response, then at peak parasitemia, switched to a Th2 
response with IL-10 production (50).  IL-10 also has been shown to suppress macrophage 
function (51).  IL-10 downregulates pro-inflammatory cytokine production, and has been shown 
to down-regulate TNF-α over-production from monocytes (52), (53).  Induction of IL-10 
synthesis by IL-12 serves as a negative feedback loop by which IL-12 limits its own pro-
inflammatory effects (54).  It has been demonstrated that the serum levels of IL-10 correlate with 
disease severity in severe malaria, and were up to three times higher than in those with 
uncomplicated malaria (33).  Ratios of IL-10/IL-12 were shown to be higher in children with 
severe malaria than those with mild malaria (29). 
Plasma levels of TNF-α and IL-10 have been shown to be lower in children with SMA 
relative to those with mild or uncomplicated malaria (29).  Children with SMA also show a low 
IL-10 level relative to TNF-α level (55), (56), (29), (57).  IL-10 may prevent development of 
SMA by controlling excessive levels of TNF-α (58).  Increased IL-10 production has been also 
associated with quicker malarial parasite clearance (59), and is an important regulator in 
protecting against malarial anemia and the harmful over-production of TNF-α.  
Pro-inflammatory cytokines IL-12, IFN-γ and TNF-α increase NO production through 
the enzyme inducible NO synthase (iNOS), while anti-inflammatory cytokines such as IL-10 
decrease NO production (60).  NO is produced by monocytes, macrophages, hepatocytes and 
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other cells and eliminates pathogens through oxidative toxicity (61).  Through iNOS, large 
amounts of NO can be produced for sustained periods of time.  There are a number of 
contradictory results in studies addressing the role of NO in malaria.  It has been suggested that 
the ability to produce more NO is protective against severe malaria (62), (63), (64).  NO has also 
been shown to be protective against blood stage parasites in murine malaria (31).  One way NO 
aids in protection in malaria is thorough destruction of gametocytes (65).  NO is a cytotoxic free 
radical that has been shown to be important in parasite clearance by monocytes, macrophages 
and polymorphonuclear lymphocytes (66), (67).  It has been shown to be protective through the 
downregulation of ICAM-1, thereby decreasing parasite vascular adherence (68).  NO produced 
from upregulation of iNOS by TNF-α, has been implicated in the pathogenesis of severe malaria 
such as coma, acidosis, and hypoglycemia, and poor prognosis (69),(70), (71).  Patients with 
mild malaria had significantly higher levels of iNOS expressed by monocytes than those with 
severe malaria, suggesting it may be an important protective factor in malaria (64),(72).  In vitro, 
NO has been shown to suppress the growth of Plasmodium falciparum (66).  
1.2.5 Cerebral Malaria 
Plasmodium falciparum-infected erythrocytes, particularly those with mature 
trophozoites, can adhere to the vascular endothelium of blood vessel walls instead of freely 
circulating through the bloodstream.  Parasite adhesion is likely dependent both on age and 
exposure of the host.  Vascular adhesion of pRBC is similar to that of leukocytes, undergoing 
adhesion, rolling, tethering, before firmly attaching.  Parasite adhesion involves CD36 and 
chondrioton sulfate (CSA) receptors on host cells, and both ICAM-1 and vascular cell adhesion 
molecule (VCAM)-1 (13).  Sequestration of infected erythrocytes in the post-capillary venules of 
 11 
the brain causes CM, which is associated with high mortality.  Parasite sequestration may 
enhance parasite survival by preventing their destruction in the spleen (73). 
CM is characterized clinically by reduced consciousness and coma, seizures, metabolic 
acidosis, hypoglycemia and retinal hemorrhaging (74).  CM is prevalent in areas of moderate and 
seasonal transmission, and frequent in children (75).  Children who recover from CM typically 
do so within 48 hours (74).  Parasites adhere to the endothelial wall, which hinders the flow of 
arteriole blood to tissues; the brain particularly is sensitive to this deprivation.  About 10% of 
children who recover from CM will have suffer sustained neurological damage such as 
blindness, deafness, or cognitive deficits (76), (77).  Acidosis can lead to coma in CM, which is 
associated with poor prognosis (78).  Accumulation of infected erythrocytes favors local 
development of cytokine-mediated inflammatory reactions which can damage endothelial cells 
and alter nervous system function (41).  Cytoadherence of parasitized RBCs is due to interaction 
of pRBC ligands and receptors on endothelial cells, namely ICAM-1 and (VCAM)-1 (79).  
Soluble levels of both of these molecules have been positively correlated with disease severity in 
human malaria (80).  
1.2.6 Malarial Anemia 
Severe P. falciparum malaria in African children is frequently characterized by severe 
anemia, hypoglycemia, hyperparasitemia, and respiratory distress (81), (82), (83).  SMA is 
responsible for the largest amount of morbidity and mortality associated with P. falciparum 
malaria (84).  SMA in Africa is seen most frequently in areas of very high malaria transmission 
(75).  Those most at risk are pregnant women and children under 2 years of age (85), (75), (86).  
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The WHO defines SMA in humans as having both a parasitemia of greater than 10,000 parasites 
μL -1 and a Hb concentration of less than 5 g/dL or a hematocrit (Hct) of less than 15% (87). 
Reference values for Hb and Hct vary in different populations, and are unknown in many 
tropical areas of the world.  Typically, malarial anemia as having a Hb concentration of less than 
8 g/dL or less than a 24% Hct (88).  Malarial anemia is also defined as Hb concentration two 
standard deviations below the mean.  Anemia associated with malaria is complex, not resulting 
from a single source, with a wide spectrum of clinical manifestations.  Malarial anemia may 
occur in the absence of overt clinical symptoms and is often disproportionate with parasitemia.  
Peripheral parasitemia can underestimate parasite burden due to parasite sequestration (89), 
which could partially explain why the relationship between level of parasitemia and degree of 
anemia are not always correlated in acute malaria. 
Malarial anemia is caused by a number of factors including the excess removal of 
nonparasitized RBCs, immune destruction of parasitized and non parasitized RBCs, and bone 
marrow dysfunction (90).  There are two main clinical patterns of malarial anemia: chronic and 
acute (91).  Chronic malarial anemia is commonly seen in children that live in malaria-endemic 
areas and is characterized by a more long-term and controlled parasitemia (43).  In chronic 
malarial anemia, phagocytized Hz is commonly seen in blood films.  The clinical presentation 
appears several weeks prior and includes a low grade fever, general ill health and in some 
instances, splenomegally (43).  The marrow is hyperactive in chronic malaria, and anemia is 
primarily caused by dyserythropoiesis and no reticulocyte release (92).  The mechanism of bone 
marrow inhibition in the presence of EPO in malaria is not well understood, but may be due to 
the release of cytokines, such as TNF-α (93), macrophage dysfunction due to ingestion of Hz 
(94) or effect of parasite products on bone marrow (92).   
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During acute malarial infections, clinical symptoms may appear prior to the onset of 
anemia, however the anemia is rapid once it appears (43).  Suppression of bone marrow in acute 
malaria is partly a response to a decrease in erythropoietin (EPO) (90), which is downregulated 
by pro-inflammatory cytokines.  Drop in Hb and Hct can be due to the decline in parasitemia 
post-treatment, or from the destruction of uninfected RBCs (43).   
1.2.6.1 Types of Anemia 
There are three main functional classifications of anemia which are based on 
abnormalities in erythron function which are clinically recognizable (95).  They are 
hypoproliferative, maturation disorder, and hemorrhagic or hemolytic anemia.  Hypoproliferative 
anemia is usually associated with acute or chronic inflammatory disease (95).  It can also be due 
to iron deficiency, a decrease in EPO response or marrow damage (suppression of early stem-cell 
proliferation) (95).  Hypoproliferative anemia is characterized by having normocytic and 
normochromic erythrocytes, but with a low reticulocyte index (<2.0) relative to the severity of 
anemia (95).  In maturation disorders there is either a micro- or macrocytosis, combined with a 
low reticulocyte index, abnormal red cell precursors, and a proliferative marrow (95).  
Maturation disorders are  either due to cytoplasmic maturation defects which characterized by a 
decrease in Hb synthesis resulting in microcytosis, or due to nuclear maturation defects, 
characterized by a macrocytosis (95).  Cytoplasmic maturation defects are caused by iron 
deficiency, defects in Hb synthesis or defects in mitochondrial function and porphyrin synthesis 
(sideroblastic anemias) (95).  Hemorrhagic/hemolytic anemias also show normocytic and 
normochromic RBCs (95).  Hemolytic anemia is a disorder in which the RBCs are destroyed 
faster than the bone marrow can produce them (95). 
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1.2.6.2 Hematological Perspective 
 
In malaria, monocytes phagocytose pRBCs and Hz, and are involved in presentation of 
antigen and the production of cytokines.  Blood monocytes also synergize with antibodies to 
inhibit parasite growth by antibody-dependent cellular inhibition (96).  After ingestion of Hz, the 
function of monocytes and macrophages is severely altered (94).  It has been suggested that 
macrophage function may also be altered by the binding of infected cells to host cell receptors 
CD36 or CD51 (97). 
Lymphocytes are categorized into two distinct cell lines, which are morphologically 
identical but distinguishable by cell-surface markers. B cells are the plasma cells and memory 
cells, and are responsible for humoral immunity.  T cells are responsible for both cell-mediated 
immunity and for activating B cells.  Lymphocyte function in malaria includes antibody 
production and parasite killing.  Reactive lymphocytes and plasma cells are increased for a short 
time during malaria, especially in acute malaria (98), (88).  Neutrophils are important in 
mediating phagocytosis of Plasmodium falciparum forms (99).  Excess pigment in neutrophils 
and macrophages and an elevated neutrophil count are indicators of poor prognosis (100). 
PLT function in promoting blood clot formation, preventing bleeding, and repairing 
damaged vessels.  PLT, as with RBCs, are produced within the bone marrow and originate from 
megakaryocytes.  Thrombocytopenia is a decreased production of PLT due to suppression of 
erythropoiesis by pro-inflammatory cytokine over-secretion (101).  Thrombocytopenia is thought 
to be caused by increased sequestration in the spleen, immune-mediated destruction, and 
decreased PLT survival (102).  PLT have been shown to bind parasitized RBC via the PLT 
surface glycoprotein CD36 (103), and may contribute to the occlusion in vasculature during 
malaria.  Thrombocytopenia and strong PLT stimulation are associated with falciparum-malaria 
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(104).  PLT have also been shown to be a factor in pathogenesis of malaria through adhering 
with the sequestered pRBC, impairing blood flow which results in decreased tissue perfusion 
(105), (106).  Mean platelet volume (MPV) gives information about PLT production in bone 
marrow.  New PLT are larger resulting in an elevated MPV when increased numbers of PLT are 
being produced (43).  MPV has shown to decrease with increasing parasitemia, but after parasite 
clearance, increased significantly to counterbalance the loss of PLT during parasitemia (107). 
Most RBCs are destroyed by the parasite during schizogony, by host immune response 
through phagocytosis by monocytes and macrophages, by opsonization through 
immunoglobulins and complement, or less frequently through natural killer cells and antibody-
dependent cytotoxicity (108).  In addition to removing pRBCs, the spleen is capable of “pitting”, 
which is the extraction of young parasites from the RBC (109).  In SMA, destruction of non-
parasitized RBCs is what accounts for the majority of the decrease in Hct, whereas in 
uncomplicated malaria, it accounts for only 10% of the total RBC loss (110).  In acute malarial 
anemia, the destruction of non-parasitized RBCs is up to eight and a half times that of parasitized 
RBCs (111).  In addition to hemolytic anemia, there is also a dyserythropoiesis in malarial 
anemia.  Bone marrow erythroid cells are increased in dyserythropoiesis, but RBC output is 
decreased, resulting from bone marrow dysfunction (91).  Pro-inflammatory cytokines, such as 
TNF-α have been implicated in bone marrow depression (93).  Administration of recombinant 
TNF-α in vitro inhibits the proliferation of hematopoietic stem cells (112) and in vivo has been 
shown to induce early dyserythropoiesis in mice with malaria (93).  
The three factors for determining anemia from hematological panels are decreases in the 
RBC count, Hb and Hct.  Hb is necessary for the transport and delivery of oxygen throughout the 
body.  Hct is the percent volume of the blood that is taken up by the RBCs.  The Hb count 
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divided by the Hct gives the mean cell hemoglobin (MCH).  A low MCH could indicate that 
there is a coexistent microcytic anemia (43).  Loss of Hb in malarial anemia also occurs before 
the pRBC is destroyed.  Up to 75% of the Hb in the RBC can be digested by parasite (113). 
The mean corpuscular volume (MCV) provides a measurement of the average size of the 
red blood cell, which is useful in determining the factors of anemia.  An elevated MCV indicates 
macrocytic RBCs, while a decreased MCV is indicative of microcytic RBCs, such as seen in 
anemia associated with iron deficiency (95).  Mean corpuscular hemoglobin concentration 
(MCHC) is a calculation of the percentage of Hb in the RBC.  Hypochromia is an anemic 
condition in which the percentage of Hb in RBCs is abnormally low (decreased MCHC), 
resulting in decreased oxygen carrying capacity (95).  Red cell distribution width (RDW) is a 
calculation of the variation in the size of RBCs.  Increased red cell population dispersions or red 
cell distribution width (RDW) has been observed in malaria, and has been attributed to the red 
cell response to malarial parasite, and correlated with the degree of macrocytosis (114).  Low 
RDW signifies a normal, homogeneous population of cells, where as an increased RDW signifies 
heterogeneity in cell size as a result of active hemtaopoiesis due to large immature red cells 
(reticulocytes) (95).  RDW can also be used as a marker of release of early erythrocytes and 
reticulocytes (95).  A study in Ghanaians with falciparum-malaria showed that high RDW 
correlates with the initial levels of EPO, suggesting that there is a quick, reversible suppression 
of the bone marrow response to EPO during malaria (115).  
1.2.6.3 Hematological Profile during Acute Malaria 
 
Leukopenia during acute falciparum-malaria is common in non-immune adults (43).  
Changes in total WBC in malaria are generally reflective of neutrophil counts, hence 
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neutropenia, due to increased neutrophil margination, is common in acute malarial infections 
(43).  Pro-inflammatory cytokine release, such as IL-12 induces neutrophil release from the 
marginating pools.  Attraction of neutrophils to the site of inflammation is caused by chemotactic 
factors including complement (51).  Lymphopenia is common in acute malaria of non-immune 
adults, and appears to resolve within 72 hours of anti-malarial treatment (43).  But in some cases, 
more common in children with acute malaria, there is a mild lymphocytosis rebound (43).  
Monocytosis is common in children and non-immune adults with acute malaria (116).  Acute 
infections in non-immune people present in mild to moderate thrombocytopenia, which is less 
frequent in immune and semi-immune populations (117).  Adults with acute uncomplicated 
malaria have >90% RBC loss accounted for by the destruction of nonparasitized RBCs (118), 
therefore anti-malarial treatment will only influence one in ten RBCs and the recovery from 
anemia will occur rapidly.  As well, non-immune individuals have suppression of erythropoiesis 
in acute malaria (119), due, in part, to the overproduction of TNF-α (93).  There is a decrease in 
Hb after treatment of acute malaria, which has been shown to correlate with the level of 
parasitemia when the patient was admitted to the hospital (91).  
1.2.6.4 Hematological Profile During Chronic Malaria 
 
Leukocytes play an important role in malaria through phagocytosis, cytotoxicity, and 
cytokine production.  Leukocytosis is common in severe and complicated malaria, and has been 
associated with severe disease (120).  Neutrophils function in phagocytosis, respiratory burst, 
and release of defensins during malaria.  Neutrophilia is seen in patients with severe malaria and 
has been associated with poor prognosis (116).  Monocytosis is less common in children with 
chronic malaria.  MPV has been shown to be increased in children with malaria (121), which 
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may be due to compensation for peripheral PLT destruction through the early release of PLT 
from the bone marrow.  In chronic malaria, dyserythropoiesis and functionally ineffective 
erythropoiesis are the primary factors in anemia (88), (92).  Chronic malaria is characterized by a 
low grade parasitemia, slow recovery and long-lasting anemia (91).  
1.2.6.5 Impact of Cytokines and Effector Molecules on Hematological Outcomes 
 
Monocytes and macrophages function in phagocytosis, release of cytokines, reactive 
nitrogen intermediates, lysozymes and other cytotoxic molecules (51).  Pro-inflammatory 
cytokines IFN-γ and TNF-α activate monocytes to induce phagocytosis and release of other 
cytokines and effector molecules, whereas anti-inflammatory cytokines, such as IL-10, prevent 
the overproduction of pro-inflammatory cytokines through feedback inhibition (122), (123), (60).  
A high pro- to anti-inflammatory cytokine ratio is associated with higher Hb concentrations 
(124), whereas overproduction of TNF-α and decreased IL-10 levels are associated with low Hb 
concentrations (125).  A balance between Th-1 and Th-2 responses is critical in the outcome of 
the pathogenesis of malaria.  Pathogenesis in malaria is also dependent upon the order of 
cytokine exposure, which determines the function of macrophages and other immune cells (126). 
The overproduction of TNF-α during malaria has been shown to impact RBC production 
through both ineffective erythropoiesis and suppression of erythropoiesis. (127).  Erythropoiesis 
is controlled by EPO, secreted by the kidneys.  High levels of EPO stimulation cause a shift of 
marrow reticulocytes into the blood circulation.  Chronic and acute inflammation influence iron-
deficient erythropoiesis since inflammatory cytokines suppress EPO and stem-cell proliferation.  
Key cytokines involved in the suppression of EPO are TNF-α, IL-1, and IFN-γ, and effector 
molecules such as NO (127).  In children with malarial anemia, NO is elevated and has been 
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inversely correlated with levels of Hb (128).  Increases in plasma TNF-α during acute 
inflammatory infections directly suppresses EPO, and blocks the release of iron from 
reticuloendothelial stores (129). In chronic infections, IFN-γ has been shown to suppress 
erythroid precursor growth.  Inflammatory cytokines impact RBC survival, production, and 
interfere with the delivery of iron to the erythroid marrow, resulting in a hypochromic anemia 
(95). 
1.2.7 Animal Model Systems for Malarial Research 
Malaria is a global health threat with an expanding number of cases each year.  The 
situation is complicated by the increase of anti-malarial drug resistance and the lack of an 
effective vaccine.  Understanding the immunologic basis of protective immunity and 
identification of novel therapeutic targets are therefore increasingly important.  A model system 
is required for investigation of molecular- and mechanistic-based immunologic studies for use in 
vaccine and pharmacologic trials.  There are virtually no longitudinal cohort studies looking at 
cytokines and hematology during P. falciparum infection in children.  This is complicated due to 
many factors including the limited amount of blood that can be taken from children, the actual 
time of primary infection, duration of primary infection, and occurrence of subsequent malarial 
infections.  Therefore animal models are able to provide an ideal and controlled model to 
examine the pathogenesis of malaria over time.   
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1.2.7.1 Plasmodium falciparum and Plasmodium coatneyi 
 
An effective disease model should closely mimic the pathogenesis of malaria seen in 
humans.  Non-human primates are and ideal candidate because they are susceptible to many 
species of Plasmodium and have humoral and cellular responses similar to those in humans 
(130).  Macaques used in malaria research include pigtailed (M. nemenstrina), cynos (M.  
fascicularis), and rhesus (M. mulatta).  Of these three species, rhesus are the best characterized 
and the most widely available.  Plasmodium coatneyi is a simian malarial parasite that shares 
many clinical and pathological similarities to severe falciparum malaria in the human host (130).  
Rhesus infected with P. coatneyi have been shown to be a valid model system for CM (131).  
Rhesus with P. coatneyi-malaria share many pathologic characteristics are similar to humans 
with CM, such as presence of knobs, binding pRBC to endothelial cells, and the pattern of 
sequestration in the brain, evident from synchronized appearance of ring stage parasites and 
absence of late trophozoite/schizonts in the peripheral blood (4), (132). 
Although the natural host for P. coatneyi is M. fascicularis, the best experimental 
vertebrate host of P. coatneyi has been the rhesus monkey.  Blood induced infection in rhesus 
can be explosive with 33% mortalities in intact monkeys and up to 100% mortality in 
splenectomized monkeys. (130).  P. coatneyi is a tertian malaria, completing one asexual life 
cycle every 48 hours.  The species was discovered by Eyles in the Anopholes hackeri mosquito 
(130).  One year later in 1962, coatneyi was isolated from M. fasicularis, it’s natural host, in 
which it produces a mild persistent infection (130).  P. coatneyi in the rhesus monkey results in a 
rapid developing, high parasitemia (300,000-500,000 parasites/mm3), which is often fatal when 
left untreated (130).  Cytokine profiles in rhesus with coatneyi-malaria resemble human cytokine 
profiles in falciparum-malaria (133), (132).  However, if animals are treated with anti-malarials 
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at a 5% parasitemia, the infection remains sub-clinical for CM.  Experimental infections of 
rhesus with P. coatneyi may be characterized by jaundice, anorexia, listlessness, fever, anemia, 
and splenomegally in spleen intact animals (130).   
Sequestration of mature schizonts in coatneyi-malaria requires that blood films be 
performed at 24-hour intervals during the course of infection to monitor parasitemia.  The 
prepatent period (before clinical symptoms of disease) ranges from 10-14 days, and peak 
parasitemia occurs between the 7-9 days PI (130).  The parasite sequestration rate in the 
microvasculature in P. coatneyi infected rhesus macaques is approximately 80%, which is 
comparable to that of cerebral falciparum-malaria in humans (134).  P. coatneyi exhibits many 
clinical manifestations similar to P. falciparum and is a valid model system for CM.  Thus, it 
may represent a valid model system for examining malarial anemia associated with P. 
falciparum.   
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2.0  SPECIFIC AIMS AND HYPOTHESES 
The goal in this study is to examine the immunopathogenesis of malaria in a potential 
model system for malarial anemia: rhesus macaques (Macaca mulatta) infected with 
Plasmodium coatneyi.   
2.1 SPECIFIC AIM 1 
Characterize the hematological profile during P. coatneyi-malaria infection, and 
determine if there is an association between hematological profiles and disease manifestations. 
2.1.1 Hypothesis 
Parameters of disease severity, such as a decrease in Hb and Hct or change in platelet 
levels are correlated with changes in parasitemia, and necessary factors to characterize anemia 
associated with malaria. 
2.1.2 Rationale and Interpretation 
  To test this hypothesis, four adult, malaria-naïve rhesus monkeys were infected with P. 
coatneyi (1 x 106 pRBC from a donor monkey).  On days 0, 2, 5, 7, 8 (peak parasitemia), 10, 15 
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(7 days post-anti-malarial treatment) and 22 (14 days post-treatment) 34, 42, and 56, and 150 PI, 
venous blood (0.5 mL) was collected in EDTA-containing vacutainer tubes for hematological 
analyses using a Coulter Counter.  A CBC and differential was performed at each time point.  
Pre-infection samples from day 0 were used as baseline values for each of the four animals.   
  The hematological panels examined were: white blood cell (WBC) count, LY, MO, MPV 
and PLT counts.  Red cell indices included RBC count, Hb, Hct, RDW, MCV, MCH, and 
MCHC.  These values were analyzed relative to baseline using the Mann-Whitney U for 
statistical significance.  Hematological indices were also compared to the parasite burned at 
different time points to examine the hematological regulation during malaria in rhesus macaques.  
Likewise, the infection was sectioned into an acute phase, which was from day 0 (initial 
infection) through day 15 PI (primary parasite clearance) and a chronic phase of infection, which 
was from day 22 [re-emergence of parasitemia (secondary)] through day 150 PI (complete 
parasite clearance).  Regulation of hematological parameters was compared to disease 
progression during both the acute and chronic phases of malaria.  Significance was tested by 
calculating levels of significance using randomization/permutation tests to obtain p-values for 
Pearson correlations. 
2.2 SPECIFIC AIM 2 
Determine the profile of cytokine and effector molecule production associated with  P. 
coatneyi-malaria in rhesus macaques, and to determine if changes in soluble inflammatory 
mediators is regulated at the transcriptional level in circulating blood mononuclear cells. 
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2.2.1 Hypothesis 
There is a unique profile of soluble cytokine and effector molecules regulated by 
transcriptional changes in circulating blood mononuclear cells associated with the pathogenesis 
of blood-stage malaria that can be used to predict disease severity and clinical outcomes. 
2.2.2 Rationale and Interpretation 
  To test this hypothesis, four malaria-naïve adult rhesus macaques, Macaca mulatta were 
infected intravenously on day 0 with 1 x 106 Plasmodium coatneyi-infected erythrocytes.  
Parasitemia was monitored daily throughout the course of the infection by peripheral blood 
smears from a tail-prick.  Venous blood (8 mL) was collected in ACD vacutainers on days 0, 2, 
5, 7, 8 (peak parasitemia), 10, 15 (7 days post-treatment) and 22 PI (14 days post-treatment).  
Baseline values were established from the pre-infection samples on day 0 for the four animals.   
PBMCs were isolated from whole blood using a Lymphocyte Separation Media gradient via 
centrifugation.  Cells were washed and re-suspended in complete DMEM.  Plasma was 
aliquotted, SNAP frozen, and stored at -80°C for use in soluble cytokine quantification using 
ELISA.  PBMCs were centrifuged, SNAP frozen, and stored at -80°C for RNA isolation.  Plasma 
was examined for levels of soluble cytokines (IL-10, IL-12 IFN-γ and TNF-α) by ELISA and 
effector molecule (NO) using the Greiss reaction for total NO.  Quantitative sandwich enzyme 
immunoassay technique was used with commercially available reagents.  Each sample was 
assayed in duplicate, and the mean of the two values were used in all analyses.   
  RNA was isolated from PBMC pellets and by the Guanidinium Thiocyanate (GITC) 
method.  Total RNA (1µg) was reverse transcribed into cDNA using an ABI GeneAmp 9700.  
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Gene expression of IL-10, TNF-α, IL-12, and IFN-γ were analyzed in triplicate using real time 
RT-PCR on an ABI Prism 7700 Sequence Detection System, using gene-specific primers and 
probes.  Primers for iNOS were also tested in rhesus cDNA, but the levels could not be detected.  
For each reaction plate, non-template controls (NTC) were added in quadruplicate.  β-actin was 
used as an endogenous control gene.  
  Due to the lack of information available for macaque mRNA sequences, Taqman primer 
and probe sets specific for human cDNA were tested for cross-reactivity with rhesus cDNA.   
The cDNA was amplified for 40 cycles.  Data was analyzed using the –ΔΔCT method where the 
endogenous control gene cycle threshold (CT) value was subtracted from the experimental gene 
CT for each sample.  The ΔCT for each experimental sample was then subtracted from the ΔCT 
of the baseline control sample.  Fold change was expressed as 2-ΔΔCT relative to baseline 
conditions. 
  Plasma and transcript cytokine levels from ex vivo PBMCs were expressed as mean ± 
standard error of the mean (SEM).  Regression analysis was used to determine the correlation 
between variables.  The plasma level of cytokines was graphed against transcript levels to 
determine if plasma levels are regulated at the gene expression level in PBMC.  To examine the 
patterns of immune regulation, levels of pro-inflammatory cytokines were compared to levels of 
anti-inflammatory cytokines. 
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2.3 SPECIFIC AIM 3 
Determine if there is a correlation between the hematological profiles and soluble 
inflammatory mediators (cytokine and effector molecule dysregulation). 
2.3.1 Hypothesis 
Dysregulation of cytokine and effector molecule production promotes changes in the 
hematological profile and clinical outcomes of P. coatneyi infection in rhesus macaques.   
2.3.2 Rationale and Interpretation 
  Plasma and transcript levels of cytokines (IL-12p40, IFN-γ, IL-10 and TNF-α) and effector 
molecules (NO) were compared with parasitemia, Hb, Hct, and PLT levels over the course of 
infection (days 0-22 PI).  Cytokine production was examined relative to MO, NEU, LY, WBC 
and RBCs.  Ratios of anti-/pro-inflammatory cytokines were examined relative to markers of 
disease severity (Hb, Hct, PLT and parasitemia).  Statistical analyses were performed to 
determine if the levels of cytokines and effector molecules over the course of the infection 
significantly correlated with the hematological indices and clinical parameters of disease severity 
using and Mann-Whitney U and randomization/permutation analysis for determining p-values 
for Pearson-correlations. 
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3.0  MATERIALS AND METHODS 
3.1 RHESUS/COATNEYI-MALARIAL INFECTION 
3.1.1 Experimental Animals 
One adult male malaria-naïve rhesus macaque (14.3 kg) (M. mulatta) of Indian origin 
was used for the initial trial infection to provide sufficient quantities of inoculum for the study.  
Four adult female rhesus macaques (4.8-7.0 kg) of Indian origin were used in the study.  Animals 
were housed according to American Association of Laboratory Animal Care Standards in a 
(AALAC-accredited BSL2+) primate facility at the University of Pittsburgh (Pittsburgh, PA) 
under the direction of a qualified veterinarian.  All monkeys were obtained commercially and 
free of natural malaria infections.  The study was performed in accordance with the animal use 
protocols approved by the Institutional Animal and Use Committee (IACUC) at the University of 
Pittsburgh, School of Medicine.   
3.1.2 Malarial Infection 
3.1.2.1 Initial Infection of M11700 
 
One vial of 0.5mL P. coatneyi-infected erythrocytes (Parasite Stock 8-38, 1.Sept, 1990) 
was generously donated from the laboratories of Dr. William Collins at the Centers for Disease 
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Control and Prevention, Department of Parasitic Infectious Diseases, Atlanta GA.  P. coatneyi 
cannot be cultured in vitro, therefore one rhesus macaque was used to grow a supply of parasites 
for use in the subsequent malaria infection of four rhesus macaques.  Frozen parasite stock was 
thawed in a 37°C waterbath for 1-2 minutes and transferred to a sterile 50 mL centrifuge tube.  
To prevent lysis, the parasites were treated with a series of decreasing salt concentrations.  A 
12% NaCl solution (0.2 mL/mL of thawed parasite stock) was added at a rate of 1-2 
drops/second. The tube was vortexed, allowed to stand for three minutes and 1.6% NaCl solution 
(10 mL/mL of thawed parasite stock) was added at a rate of 1-2 drops/second.  The solution was 
vortexed, centrifuged at 400 x g for 10 minutes and supernatant was decanted.  The final gradient 
of 0.9% NaCl/0.2% dextrose (10 mL/mL of thawed parasite stock) was added dropwise in same 
fashion as described above.  The solution was vortexed, centrifuged at 400 x g for 10 minutes 
and supernatant was decanted.  Parasites were re-suspended in 2 mL sterile USP-grade 0.9% 
NaCl, drawn up in a syringe and used for inoculation of the monkey. 
For the initial infection, M11700 was sedated with 10mg/kg of Ketamine IM, and 
infected with 1 x 106 P. coatneyi-infected erythrocytes, IV in the saphenous vein using a 23g 
butterfly catheter.  The line was flushed with 3 mL of USP-grade 0.9% NaCl solution.  
Parasitemia was monitored daily with thin films of peripheral blood from a tail-prick using a 
disposable lancet.  Slides were fixed with methanol, stained with Giemsa (pH 7.25) for 45 
minutes, and parasites were enumerated microscopically under oil immersion.  Parasitemia was 
quantified by counting the number of pRBCs relative to 10,000 total RBCs, yielding a percent 
parasitemia.  Parasitemia was also quantified as number of parasites/mm3 of blood by taking the 
number of infected RBCs multiplied by the total number of RBCs divided by 1,000. 
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Venepuncture (9.5 mL ACD, 0.5 mL EDTA blood) was performed on days 0, 2, 5, 7, 9, 
and 19 PI for hematology and cytokine profiles.  Parasitemia peaked on day 12 (7.0%).  At peak 
parasitemia, the animal was sedated and 40 mL of venous blood was drawn in ACD for use in 
making new parasite stock solutions.  Additionally, 9.5 mL (ACD) and 0.5 mL (EDTA) of 
venous blood was drawn for cytokine and hematological profiles, respectively.  At peak 
parasitemia on day 12 PI, M11700 was treated with 150 mg chloroquine and 150 mg quinine PO 
at 0 and 48 hours.  The infection was completely cleared by day 16 PI and remained clear for the 
next 40 days of monitoring by thin film blood smears. 
3.1.2.2 Parasite Preparation 
 
Parasites from M11700 were prepared for freezing using 40 mL whole blood from peak 
parasitemia, which was centrifuged at 400 x g for 10 minutes.  Plasma was separated, aliquotted 
and frozen at -80°C.  Blood was washed twice in Roswell Park Memorial Institute media (RPMI) 
1640, (Invitrogen, Carlsbad, CA, US) and centrifuged at 400 x g for 10 minutes.  Supernatant 
was carefully decanted without removing the brown layer on top of the RBCs.  The volume of 
packed cells was estimated at 18 mL.  To prevent the parasites from lysing during the freezing 
process, increasing salt concentrations were gradually added.  An equal amount of glycerolyte 
(1/3 the volume of the packed cells) was added at a rate of 1-2 drops/second.  The tube was 
vortexed and allowed to stand for five minutes.  The second glycerolyte gradient was added 
(amount equal to 4/3 the original volume of the packed cells), at a rate of 1-2 drops/second.  The 
solution was vortexed and aliquotted at 1.0 mL/cryovial.  The vials were placed in a slow 
freezing apparatus (at a rate of -1°C/minute), and placed in a -80°C freezer.  After 24 hours, the 
cryovials were transferred to liquid nitrogen storage. 
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3.1.2.3 Experimental Infection 
 
Four rhesus macaques were infected intravenously with a fresh inoculum of 1 x 106 
viable Plasmodium coatneyi-infected erythrocytes, which had been frozen from the previous 
infection of the donor monkey infected with a thawed cryostabilate of P. coatneyi.  From 
infection onward, parasitemia was monitored daily by thin blood smears from a tail-prick.  Thin 
blood films were prepared by the method of Earle and Perez (135), fixed with methanol, stained 
with Giemsa, examined microscopically under oil immersion and parasitemia was enumerated.  
Malarial infections were recorded as the percentage of infected RBCs per 10,000 RBCs counted, 
with a minimum of twenty fields in each thin film counted, and also as parasites/mm3 of blood (as 
described above). 
Day 2 50 7 8 15 2210
P. coatneyi infection
Peak Parasitemia
PBMC Isolation
• total RNA Isolation
• Real time RT-PCR
Hematological Measures
• Complete blood count
Plasma
• Cytokine & effector 
molecule analyses
Treatments
42 55 56 70 1501613 3433
Acute Infection D0-15 PI Chronic Infection D22-150 PI
Venepuncture
Parasite Clearance
Complete blood count
At least 1 animal
Undetectable levels 
of pRBC in at least 1 
animal
1) Chloroquine 150 
mg & Quinine 150 
mg, PO (0,48 H)
2) Chloroquine 7 
mg/kg, IM SID x 5 
days & Quinine 20 
mg/kg IM (0,48 H)
3) Mefloquine (20 
mg/kg) PO SID
Hematological Measures Only
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Figure 4: Experimental Design 
 
 31 
 Acute infection was defined as the primary infection from days 0-15 PI, which was 
two weeks after the initial treatment and after the first parasite clearance (Figure 4).  Chronic 
infection was defined as the duration after the primary acute infection which includes the re-
emergence of parasites after initial clearance (day 22-day 150 PI), followed by two subsequent 
treatment regimens.  Animals were sedated for venepuncture with 10 mg/kg Ketamine.  Venous 
blood was collected in ACD (8mL) and EDTA (0.5mL for hematology panels) vacutainers prior 
to challenge (day 0) and on days 2, 5, 7, 8 (peak parasitemia), 10, 15 (7 days post-treatment) and 
22 PI (14 days post-treatment) during infection.  Venous blood was also collected for 
hematology panels only (0.5mL in EDTA) in the same manner on days 34, 42, 56, and 150 PI 
during the chronic infection, since there is a limited amount of blood that can be withdrawn from 
the animals during a defined period.  At each time point the animals were sedated, both weight, 
and rectal body temperature were recorded.  Hematological parameters were measured using a 
Coulter Counter (Beckman Coulter, Miami, US).  Both complete blood counts (CBC) and 
differentials were performed.  Baseline values were established using the pre-challenge samples 
from day 0 for the malaria-infected animals.  Reference values were also taken from Buchl and 
Howard’s (1997) hematological values in clinically normal captive bred rhesus macaques (136) 
(Table 1).   
Animals were treated when parasitemia reached 5% or greater with chloroquine (150mg 
PO) and quinine (150 mg PO) on days 8 and 10 PI.  This treatment did not effectively clear the 
malaria infection.  Parasites were undetectable by days 15-16 PI, but all animals relapsed with 
parasites re-emerging by day 20 PI.  This enabled for the comparison between the acute primary 
infection and the chronic secondary infections.  Three animals (M2198, M10800, and M11799) 
had an increase in parasitemia of 5% or greater by day 33 PI, while M11600 had a controlled 
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parasitemia of 0.25%.  Animals were monitored and treated again on day 34 PI with combination 
therapy of quinine (20 mg/kg IM SID at 0 and 48 hours) and chloroquine (7mg/kg, IM SID x 5 
days).  This treatment regimen was not effective at completely clearing the malarial infection.  
By day 54 PI, parasitemia ranged from 1-3.5% in all four monkeys.  Mefloquine is used to treat 
coatneyi-malaria if an isolate is suspected to be chloroquine-resistant.  On day 55 PI, animals 
were treated with a single dose of mefloquine (20 mg/kg SID PO).  Parasitemia cleared by day 
70 PI, and remained clear through day 150 PI. 
 
Table 1: Normal Hematological Values in Healthy Adult Rhesus Macaques 
Leukocyte Indices Red Blood Cell Indices
WBC (x106/mL) RBC (x106/mL)
4.2-8.1 5.1-5.6
LY (%) LY** (x103/mL) Hb (g/dL)
39-72 3.1-4.1 12.0-13.1
MO (%) MO** (x103/mL) Hct (%)
1-4 0.2-0.6 37-40
NEU (%) NEU** (x103/mL) MCV (fL)
26-52 2.1-3.3 71-75
Platlet Indices MCH (pg)
Plt (x103/mL) 22.8-24.5
260-361 MCHC (g/dL)
MPV** (fL) 31.0-33.4
5-15 RDW** (%)
TEMP (oC) 12.4-13.9
37.2-39.2
** calculated from the mean +/- standard deviation of the animals preinfection
All other values from Buchl SJ, Howard B. Hematologic and serum biochemical and 
electrolyte values in clinically normal domestically bred rhesus monkeys (Macaca mulatta ) 
according to age, sex, and gravidity. Lab Anim Sci.  1997 Oct;47(5):528-33.  
 
Malarial anemia is defined in humans as Hb concentration of less than 8 g/dL or less than 
a 24% Hct, and severe malaria anemia as Hb concentration of less than 5 g/L or a Hct of less 
than 15% (87).  Since reference values for Hb and Hct vary, and are not known for many tropical 
 33 
areas of the world, anemia can be defined as Hb concentration two standard deviations below the 
mean based on age, sex, and pregnancy state.  There are no reference values for malarial anemia 
in rhesus macaques, therefore two standard deviations from both the mean Hb and Hct levels 
were calculated from the animals in this study (n=4) (Table 2).  
Table 2: Classification of Anemia in Rhesus Macaques Infected with P. coatneyi 
Characterization of Anemia based on normal values
HEMOGLOBIN HB HEMOGLOBIN
AVG (n=4) 10.7 25% Reduction 50% Reduction
STDEV 0.4113 10.675 10.675
2STDEV 0.8226 9.9 2.66875 5.3375
3STDEV 1.2339 9.4 8.0 5.3
4STDEV 1.6452 9.0
HEMATOCRIT HCT HEMATOCRIT
AVG (n=4) 33.2 25% Reduction 50% Reduction
STDEV 1.3401 33.225 33.225
2STDEV 2.6802 30.5 8.30625 16.6125
3STDEV 4.0203 29.2 24.9 16.6
4STDEV 5.3603 27.9  
3.1.3 Isolation of Peripheral Blood Mononuclear Cells 
Plasma was separated, SNAP frozen and cryopreserved at -80°C.  Blood cells were re-
suspended in media, layered over Lymphocyte Separation Medium (Mediatech/Cellgro, 
Herndon, VA, US) and centrifuged at 2000 rpm for 30 minutes.  Cells in the interface were 
collected and washed twice with RPMI 1640 supplemented with 10% Fetal Calf Serum (FCS) 
(Hyclone, Logan, UT, US).  Cells were cryopreserved in individual pellets and stored at -80°C.   
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3.1.4 Plasma Cytokine Determination 
Venous blood was drawn in ACD and EDTA containing tubes just prior to challenge (day 
0) and on days 2, 5, 7, 8, 10, 15, and 22 PI.  Freshly thawed plasma samples were assayed for 
levels of soluble cytokines [IL-10 (BioSource ELISA sets, Camarillo, CA, US) , IL-12 
(BioSource ELISA set Camarillo, CA, US), IFN-γ (Opt-EIA ELISA Sets, BD PharMingen, San 
Jose, CA, US), and TNF-α (Opt-EIA ELISA Sets, BD PharMingen, San Jose, CA, US) using 
quantitative sandwich enzyme immunoassay technique with commercially available reagents.  
Each sample was measured in duplicate, and the mean of the two values were used in all 
analyses.  Flat-bottomed Maxisorb (Nalge Nunc, Rochester, NY, US) plates were coated 
overnight with 100 μL of the capture antibody coating buffer (diluted to optimal concentration 
with phosphate buffered solution (PBS).  Plates were washed with wash buffer and blocked with 
200 μL blocking solution for the optimal time for each assay at 37°C.  Plasma (100 μL) was 
added to each well and allowed to incubate for 1 hour (in the case of IL-10 and IL-12, the 
incubation time was 2 hours, and biotinylated capture antibody was added prior to the 
incubation).  After several washes, biotinylated capture antibody and avidin-labelled horseradish 
peroxidase were added to each well and allowed to incubate for 30 minutes.  Plates were 
developed for 30 minutes using TMB substrate reagent set (BD PharMingen, San Jose, CA, US) 
in the dark.  The reaction was stopped using 2M phosphoric acid solution.  The absorbance was 
read on a spectrophotometer at a 450 nm wavelength.  Monoclonal antibodies against human IL-
12 are specific for the IL-12p40 subunit and react with both human and rhesus IL-12, and thus 
detect both human and rhesus IL-12 levels.  
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3.1.5 Total NO Determination 
NO is an evanescent molecule, with a half-life of 4 seconds (137) and can not be 
accurately measured in vivo.  Plasma levels of stable metabolites of NO, nitrate (NO2-) and 
nitrate (NO3-) collectively termed reactive nitrogen intermediates (RNI) are measured.  As the 
relative proportion of NO2- and NO3- is variable, the sum of the RNI is the best index of total 
NO.  Plasma levels of total NO were determined using the Greiss reaction (138), (139).  Samples 
were assayed in duplicate.  NO3- is converted into NO2- by utilizing nitrate reductase.  To each 
well, 50 μL of sample, 15 μL of de-ionized water, 10 μL of 1M TRIS (pH 7.5), 1 μL of 0.2 mM 
nicotinamide adenine dinucleotide phosphate (reduced form, (NADPH) (Sigma, St. Louis MO, 
US), 20 μL of 5 mM glucose-6-phosphate (G6P), 3 μL of 10.0 U/mL glucose-6-phosphate 
dehydrogenase (G6PDH) and 1 μL of 1.0 U/mL nitrate reductase were added on ice.  After 
incubating at ambient temperature for 2 hours, the volume in each well is divided between two 
plates and 50 μL of each Greiss Reagent I (1% sulfanilamide in 2.5% phosphoric acid) and II 
(0.1% naphthyethylenediamine in 2.5% phosphoric acid) were added to each well.  After 
incubating for 10 minutes at room temperature, the absorbance was read on a plate reader at 550 
nm. 
3.1.6 RNA Extraction 
RNA was extracted from individual PBMC pellets and by using the guanidinium 
isothiocyanate (GITC) method (140).  This extraction was performed by adding a solution 
comprised of filter-sterilized water, 25mM sodium citrate (pH 7.0), 10% Sarkosyl (MP 
Biomedicals, Irvine, CA, US), 4M of GITC (Gibco/Invitrogen, Carlsbad, CA, US) and β-
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mercaptoethanol (MP Biomedicals, Irvine, CA, US) to cells.  After incubating for 5 minutes, 2M 
sodium acetate, phenol, and chloroform/isoamyl alcohol (MP Biomedicals, Irvine, CA, US) were 
each added, and contents mixed thoroughly.  Samples were incubated on ice for 30 minutes, 
which permitted complete dissociation of nucleoprotein complexes.  Samples were centrifuged at 
3750 rpm for 20 minutes at 4oC.  The upper three quarters of the aqueous phase was transferred 
and an equal volume of cold isopropanol (MP Biomedicals, Irvine, CA, US) was added to the 
extracted RNA.  The solution was allowed to precipitate at -20oC for two days.  The precipitated 
RNA was pelleted by centrifugation at 10,000 rpm for 30 minutes at 4oC.  Isopropanol was 
decanted and evaporated.  RNA was dissolved on ice with DEPC-treated water, held on ice for 
15 minutes, and heated at 65oC for 10 minutes to solubilize RNA. 
The RNA was quantified on a spectrophotometer (Amersham Bioscience, Piscataway, 
NJ, US).  Total RNA (1µg) was reverse transcribed using random hexamers and murine 
leukemia virus (MuLV) (Applied Biosystems, Foster City, CA, US) into cDNA on a ABI 
GeneAmp 9700 (Applied Biosystems, Foster City, CA, US).  
3.1.7 Quantitative Real Time RT-PCR 
Gene expression of IL-10 (Accession Number NM_000572, Applied Biosystems, Foster 
City, CA), TNF-α, (Accession Number NM_000594, Applied Biosystems, Foster City, CA), IL-
12 (Accession Number NM_002187, Applied Biosystems, Foster City, CA), and IFN-γ were 
analyzed using real time RT-PCR on an ABI Prism 7700 sequence detection system (Applied 
Biosystems, Foster City, CA) utilizing each gene-specific primers and probes.  For IFN-γ, 
primers were designed using IDT Oligonucleotide design software (Integrated DNA 
Technologies, Inc., Coralville, IA) by the following sequence: RhIFN-γ AS Taq primer (5’-ATC 
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TGG ATC ACC TGC ATT AAA ATA TTT-3’), RhIFN-γ S Taq primer (5’-CAG CTC TGC 
ATT GTT TTG G-3’)  Probes were designed by the Primer Express software (PE Applied 
Biosystems, Inc. Foster City, CA) for the following sequence: RhIFN-γ TaqProbe (5’-FAM-CTT 
GGC TGT TAC TGC CAG GAC CCA TAT GTA A-TAMRA-3’).  iNOS (Accession Number 
NM_153292.1 Applied Biosystems, Foster City, CA) was assayed several times in these 
samples, but the levels were undetectable.  
For each reaction plate, non-template controls (NTC) were added in quadruplicate.  β-
actin (Applied Biosystems, Foster City, CA) was used as an endogenous control gene.  The 
human-specific β-actin primer and probe set, which is a good housekeeping gene for human 
PBMC, also recognized macaque cDNA from four independent samples.  Due to the lack of 
information available for macaque mRNA sequences, Taqman® primer and probe sets specific 
for human cDNA were tested for cross-reactivity with rhesus cDNA.  The cDNA was amplified 
for 40 cycles.  Data was analyzed using the ΔΔCT method where the endogenous control gene 
cycle threshold (CT) value was subtracted from the experimental gene CT for each sample.  The 
ΔCT for each experimental sample was then subtracted from the ΔCT of the unstimulated control 
sample to calculate the ΔΔCT.  Fold change was expressed as 2-ΔΔCT relative to unstimulated 
conditions. 
3.1.8 Statistical Analyses 
Plasma cytokine levels and cytokine transcript levels from non-cultured PBMC were 
measured in duplicate.  Data were expressed as mean ± standard error of the mean (SEM).  
Comparisons between groups were made using the Mann-Whitney U tests with statistical 
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significance set at p < 0.05.  Statistical significance was set at P < 0.05.  Randomization-based p-
values for Pearson correlations, with Bon Feroni corrections were calculated for all timepoints in 
the four animals for each hematological parameter against cytokine levels, parasitemia, anemia 
(Hb), and thrombocytopenia (PLT).  
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4.0  RESULTS 
4.1 CLINICAL AND HEMATOLOGICAL PROFILES: ACUTE RELATIVE TO 
CHRONIC INFECTION 
4.1.1 Course of Malarial Infection 
Throughout the course of infection, trends in parasitemia were asynchronous in all four 
animals, although the relative degree of parasite burden varied.  Parasites were detected in the 
blood on day 1 PI.  Parasitemia grew exponentially in the following days until reaching >5% 
(5.6-7-8%, corresponding to 236,320-290,160 parasites/µL) for each animal on day 8 PI (Figure 
5).  All four animals’ parasitemias peaked on day 8 PI, with the exception of M2198, which had 
a 6.2% parasitemia on day 8 PI, decreased to 3.05% on day 9, followed by a hyperparasitemia on 
day 10 PI of 8.3%.  Animals were treated with chloroquine (150mg PO) and quinine (150mg PO) 
on days 8 and 10 PI.  The animals’ parasitemias declined after the two days of treatment.  
Treatment did not fully clear the infection.  Parasitemia was undetectable by day 16 PI, however, 
all four animals relapsed, and parasites were present again by day 20 PI.  This event enabled for 
comparison of an acute primary malarial infection with a more chronic secondary malarial 
infection.  For this study, acute infection was defined as days 0-15 PI, while chronic phase of 
infection encompassed the reminder of the infection through day 150 PI.   
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Figure 5: Daily Parasitemia in Rhesus Macaques Infected with P. coatneyi 
 
During the chronic phase of infection, there were two distinct increases in parasitemia.  
The first occurred on day 33 PI.  Two animals, M2198 and M11799, had parasitemias of >6% on 
day 33 PI, while M11799 had a parasitemia of 4.8%.  M11600 had an increase in parasitemia to 
0.85% on day 29, but was able to control parasitemia to 0.25% by day 33 PI.  The animals were 
monitored and treated on day 34 with combination therapy of quinine (20mg/kg IM SID at 0 and 
48 hours) and chloroquine (7mg/kg, IM SID x 5 days).  During this time parasitemia had 
decreased and was clearing around day 37 PI.  However, parasitemia re-emerged in all four 
animals, and by day 54 PI, all four animals had parasitemias between 1-3.5%.  Mefloquine can 
be used to treat P. coatneyi, especially if an isolate is suspected to be chloroquine-resistant.  On 
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day 55 PI, a single dose of mefloquine (20 mg/kg SID PO) was administered.  The malarial 
infection cleared completely by day 70 PI, and remained clear through day 150 PI 
At each peak in parasitemia, with the exception of day 8 PI, M2198 had the highest 
parasite load among the four animals.  M2198 was also the only animal to rebound with a 
hyperparasitemia after the initial treatments on day 10 PI, with a parasitemia of 309,375 
parasites/µL, which falls in the lower range of susceptibility for CM.  M11799 had the most 
severe parasite burden on day 8 (peak parasitemia) at 290,160 parasites/µL (7.8%).  M11799 had 
a high parasitemia during the chronic infection on day 33 PI (6.2%), whereas the final increase in 
parasitemia during the chronic infection on day 54 did not increase above 1.0% in this animal.  
M10800 reached a 5% parasitemia or greater in both the acute and chronic phases of infection, 
but had a slightly lower parasite burden on each of the three peaks in parasitemia than two of the 
other three animals.  The animal that was best able to control parasite burden was M11600.  In 
the acute infection, M11600 peaked at 236,320 parasites/µL (5.6%) on day 8 PI.  During the 
chronic phase of infection, M11600’s parasitemia did not elevate above 2%.   
4.1.2 Clinical Outcomes 
Body temperature and weight were recorded at each time the animal was anesthetized for 
venepuncture and/or treatment.  Pre-infection temperature ranged from (37.72-38.5°C) (Table 3).  
Fever occurred on days 8 (peak parasitemia) and day 22, which was the first re-emergence of 
parasitemia (p<0.05 by Mann Whitney U).  M2198 and M11799 also had fevers on day 34 PI.  
There was an increase in body temperature on days 35 and 56 PI, both days where parasitemia 
had peaked again, but was not statistically significant.   
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Table 3: Clinical Observations in Rhesus Macaques Infected with P. coatneyi 
Clinical Observations
Parasitemia (/mL) D0 D2 D5 D7 D8 D10 D15 D22 D34 D42 D56 D150
M2198 0 7,020** 32,700* 99,820* 286,590** 309,375 1,410 14,560* 94,990* 3,930 129,360 0
M10800 0 4,140** 75,750* 34,725* 274,000** 31,790 0 35,360* 107,100* 1,400 23,130 0
M11600 0 4,350** 52,600* 87,740* 236,320** 21,230 0 18,720* 19,635* 6,880 61,800 0
M11799 0 7,540** 104,790* 66,348* 290,160** 12,080 1,435 10,400* 68,960* 1,990 50,600 0
Weight (kg) D0 D2 D5 D7 D8 D10 D15 D22 D34 D42 D56 D150
M2198 7.2 7.3 7.1 7.3 7.2 6.9 6.9 6.2 6.1 6.1 6.0 6.6
M10800 4.8 5.0 4.8 5.0 4.9 4.8 5.1 4.6 4.7 4.6 4.9 5.1
M11600 6.3 6.8 6.6 6.7 6.6 6.5 6.9 6.4 6.5 6.5 6.7 7.8
M11799 6.6 6.7 6.5 6.6 6.5 6.4 6.5 6.0 5.8 5.8 5.8 6.8
Temperature (°C) D0 D2 D5 D7 D8 D10 D15 D22 D34 D42 D56 D150
M2198 37.9 38.2 37.8 38.2 38.4* 36.6 37.8 39.9* 39.8 38.4 38.5 38.7
M10800 37.4 38.4 38.4 37.8 38.8* 38.5 38.6 38.6* 38.3 38.7 38.1 38.2
M11600 38.5 38.5 38.5 37.9 39.7* 38.5 38.2 39.2* 38.8 38.5 39.2 38.1
M11799 37.7 38.6 38.2 38.2 40.2* 37.9 38.5 40.0* 40.4 38.5 39.7 38.8
* Denotes P<0.05 (by Mann-Whitney U) relative to baseline levels (Day 0)
** Denotes P<0.01 (by Mann-Whitney U) relative to baseline levels (Day 0)  
Overall, M11799 showed the highest fever at the four different timepoints, with a 7.1% increase 
in temperature above baseline during the chronic phase of disease, and 6.7% increase during the 
acute phase (Table 4).  Upon parasite clearance and post-treatments body temperature decreased 
to normal range.  Parasite load was not a significant predictor of body temperature.   
Table 4: Magnitude of Weight Loss and Fever in Acute and Chronic Stages of Malarial Infection 
Percent Change over Baseline
Weight Loss ACUTE CHRONIC
M2198 -4% -17%
M10800 0% -4%
M11600 0% 0%
M11799 -3% -12%
Temperature Increase ACUTE CHRONIC
M2198 1% 5%
M10800 4% 4%
M11600 3% 2%
M11799 7% 7%  
Weight loss varied from 0-17% during the course of infection, with the largest decline in 
weight occurring in the chronic phase of infection on days 22, 34, and 42 PI, again following 
with the re-emergence of parasitemia.  The two animals that had the highest parasite burdens 
during the infection, M2198 and M11799, also had the largest decline in body weight during the 
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chronic infection at 17% and 12%, respectively.  However, on day 10 (hyperparasitemia) when 
the parasitemia was over 300,000 parasites/µL in M2198, fever was reduced, due to the 
treatment with anti-malarials on day 8 PI.  M10800 had a 4% drop in weight during the chronic 
phase of disease.  M11600 had the lowest parasite loads and had no decline in body weight 
through the course of infection, but rather weight gain. 
4.1.3 Hematological Outcomes 
Along with presence of parasitemia, Hb and Hct were used to define the level of anemia.  
Baseline levels of Hb ranged from 10.2-11.2 g/dL (mean = 10.7g/dL), and baseline Hct ranged 
from 31.7-34.9% (mean = 33.2%).  Anemia was defined as Hb and Hct two standard deviations 
below the mean, <9.9g/dL, or <30.5%, respectively.  As there was a small cohort of animals used 
in the calculation of normal ranges, a more severe anemia of four standard deviations below the 
mean (Hb, Hct), and a 25% and 50% reduction in Hb below the mean were characterized 
(TABLE 2).   
Mann-Whitney U was used to determine significant changes from baseline (p<0.05, 95% 
CI) (Table 5).  Hct, Hb, and RBC were all positively correlated (p<0.01).  Randomization tests 
were used to compute p-values for Pearson correlations, and used to determine the significance 
between parasitemia and hematological outcomes, anemia, and other hematological parameters.  
The timepoint at which the animals had the highest parasite burden was positively correlated 
with level of Hb (p<0.05).   
Hb, Hct, and RBC levels significantly increased above baseline (p<0.01) in all four 
animals on day 5 PI, also the first exponential increase in parasitemia (Table 5), which could be 
due to the absence of a robust early cytokine response, which would negatively regulate Hb 
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levels.  Anemia was defined as [Hb] <9.9g/dL, or [Hct] <30.5%.  In Table 5, anemia was 
categorized as one of the following: two standard deviations below the mean (yellow), four 
standard deviations below the mean (blue), or 25% reduction below the mean (green).  None of 
the animals had an anemia with 50% reduction in Hb or Hct below the mean (gray).  All four 
animals were anemic on days 10, 15, and 42 PI.  At least one of the animals was considered 
anemic days 2, 7, 8, 22 and 34 PI.   
Table 5: Red Blood Cell Indices in Rhesus Macaques Infected with P. coatneyi 
Red Blood Cell Indices
RBC (x106/mL) D0 D2 D5 D7 D8 D10 D15 D22 D34 D42 D56 D150
M2198 4.89 4.68 5.45** 4.34 4.66* 3.75* 2.82* 3.64 4.13* 3.93* 5.39 5.43*
M10800 4.47 4.14 5.05** 4.63 4* 3.74* 3.45* 4.16 3.15* 2.8* 5.14 4.82*
M11600 4.5 4.35 5.26** 4.1 4.22* 3.86* 3.84* 4.68 3.57* 3.44* 5.15 4.9*
M11799 4.47 3.77 4.99** 3.42 3.72* 3.02* 2.87* 4.16 4.31* 3.98* 4.4 5.24*
Hb (g/dL) D0 D2 D5 D7 D8 D10 D15 D22 D34 D42 D56 D150
M2198 11.2 10.9 12.3** 9.9 10.6* 8.7* 6.9* 8.8 9.7 8.9* 12 12*
M10800 10.2 9.7 11.6** 10.7 9.2* 8.7* 8.2* 9.4 6.7 5.9* 10.8 11*
M11600 10.7 10.5 12.4** 10.1 10* 9.1* 9.3* 11.1 8.2 7.8* 11.7 11.5*
M11799 10.6 9.2 12** 8.1 8.8* 7.1* 7.5* 10.1 10.4 9.3* 10.1 12.5*
Hct (%) D0 D2 D5 D7 D8 D10 D15 D22 D34 D42 D56 D150
M2198 34.9 33.1 37.6** 30.2 31.6* 24.6* 21.7* 27.4 30.1 28.4* 37.2 37.6*
M10800 31.7 29.4 35.4** 32.3 27.5* 26.5* 25.5* 29 20.9 18.8* 34.3 34.5*
M11600 33.5 32.4 38.4** 29.9 30.2* 27* 28.9* 34.1 25.3 24.6* 36.6 35.7*
M11799 32.8 28.1 35.6** 24.5 26.3* 20.6* 22.1* 31.6 31.6 29* 31.5 38.5*
MCV (fL) D0 D2 D5 D7 D8 D10 D15 D22 D34 D42 D56 D150
M2198 71.3 70.8 69* 69.5** 67.8** 65.5 76.8* 75.1 72.6 72.4 69.1* 69.4
M10800 70.8 71 69.9* 69.7** 68.6** 71.25 73.9* 69.6 66.4 67.2 66.6* 71.6
M11600 74.3 74.4 72.9* 72.8** 71.5** 69.8 75.2* 72.8 70.7 71.4 71.1* 72.8
M11799 73.3 74.5 71.2* 71.5** 70.5** 67.9 76.9* 75.9 73.4 72.7 71.5* 73.4
MCH (pg) D0 D2 D5 D7 D8 D10 D15 D22 D34 D42 D56 D150
M2198 22.9 23.2* 22.6 22.7 22.7 23.1 24.4* 24.2 23.5 22.5 22.2* 22.2
M10800 22.9 23.4* 23 23 23 23.4 23.8* 22.5 21.3 21 21.1* 22.9
M11600 23.8 24.2* 23.7 24.6 23.7 23.5 24.3* 23.8 23 22.5 22.7* 23.4
M11799 23.8 24.5* 24.1 23.8 23.7 23.4 26.2* 24.9 24.1 23.3 23.1* 23.8
MCHC (g/dL) D0 D2 D5 D7 D8 D10 D15 D22 D34 D42 D56 D150
M2198 32.1 32.8** 32.7* 32.7* 33.5** 35.2** 31.8 32.2 32.3 31.1* 32.1 32
M10800 32.3 33** 32.8* 33* 33.6** 35** 32.2 32.4 32 31.3* 31.6 32
M11600 32 32.5** 32.4* 33.7* 33.2** 33.6** 32.3 32.6 32.5 31.5* 31.9 32.4
M11799 32.5 32.9** 33.8* 33.2* 33.6** 34.4** 34 32.7 32.8 32.1* 32.2 33.4
RDW (%) D0 D2 D5 D7 D8 D10 D15 D22 D34 D42 D56 D150
M2198 14.1 13.3 13.7 13.5* 13.4 13 15.3 21.4 17.6* 18.8* 14.8* 14.2
M10800 12.8 12.7 12.7 12* 12.4 12.7 9.5 13.5 16* 16.8* 15.4* 12.8
M11600 13.3 13.7 13.4 13.2* 13.5 13.9 17.5 14.6 14.6* 15.5* 14.7* 13.4
M11799 12.3 12.2 12.1 11.5* 12.1 11.9 20.3 17.8 14* 14.8* 13.6* 12.3
* Denotes P<0.05 (by Mann-Whtiney U) relative to baseline levels (Day 0) Anemia defined by 2 STDEV below Mean 
** Denotes P<0.01 (by Mann-Whitney U) relative to baseline levels (Day 0) [Hb] <9.9g/dL, [Hct] <30.5%
4 STDEV below mean
[Hb] <9.0g/dL, [Hct] <27.9%
 25% reduction below Mean
[Hb] <8.0g/dL, [HCT] <24.9%
 50% reduction below Mean
[Hb] <5.3g/dL, [HCT] <16.6%  
 45 
 During the acute infection, Hb, Hct and RBCs were lowest on days 8, 10, and 15 
(p<0.05).  By day 22 they began to increase closer to baseline levels.  During the chronic 
infection, on day 34 (RBC decrease only) and 42 PI, there was again a significant decrease in 
Hb, Hct and RBC counts (p<0.05).  Hb decreased 15-38% from baseline during the acute 
infection, and 12-42% during the chronic infection, while Hct decreased 19-38% decrease in the 
acute infection and a 12-41% decrease in the chronic infection (Table 6).  The average percent 
change in Hb, Hct and RBC did not significantly change between acute and chronic phases of 
disease in the four animals.  
Table 6: Red Blood Cell Indices in the Acute and Chronic Stages of Malaria in Rhesus Macaques 
(Percent Change from Baseline) 
Red Blood Cell Indices ACUTE CHRONIC ACUTE CHRONIC
(% Decrease) (% Decrease) (% Increase) (% Increase)
RBC
M2198 -42 -26 11 11
M10800 -23 -37 13 15
M11600 -15 -24 17 14
M11799 -36 -11 12 17
AVERAGE -29 -24 13 14
Hb
M2198 -38 -21
M10800 -20 -42
M11600 -15 -27
M11799 -33 -12
AVERAGE -26 -26
Hct
M2198 -38 -21
M10800 -20 -41
M11600 -19 -27
M11799 -37 -12
AVERAGE -28 -25
MCV
M2198 -8 -3 8 5
M10800 -3 -6 4 1
M11600 -6 -5 1 -2
M11799 -7 -2 5 4
AVERAGE -6 -4 5 2
MCH
M2198 -1 -2 7 6
M10800 0 -8 4 -2
M11600 -1 -5 3 0
M11799 -2 -3 10 5
AVERAGE -1 -5 6 2
MCHC
M2198 -1 -3 10 1
M10800 0 -3 8 0
M11600 0 -2 5 2
M11799 0 -1 6 3
AVERAGE 0 -2 7 1
RDW
M2198 -8 -5 9 52
M10800 -26 -5 0 31
M11600 1 -10 32 17
M11799 -7 -11 65 45
AVERAGE -10 -8 26 36   
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During the acute primary infection, parasite burden at peak parasitemia (day 8 PI) was 
found to be a significant predictor of acute anemia, (Hb levels on day 15 (p<0.05)).  Parasite 
burden at peak parasitemia was also correlated with the level of RBCs at acute anemia (day 15 
PI) (Figure 6).  However, Hct was not predicted by parasite burden.  During the chronic 
infection, peaks in parasitemia did not significantly predict the subsequent decreases in Hb, Hct 
or RBCs.   
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*Denotes p<0.025 by randomization tests used to determine p-values for Pearson correlations 
Figure 6: Parasitemia Relative to Hemoglobin Concentrations during Malarial Infection in Rhesus 
Macaques 
 
MCHC significantly increased on days 2, (p<0.01), 5 (p<0.05), 7 PI (p<0.05) 8 (p<0.01) 
and 10 (p<0.01) PI.  Both intra- and extracellular Hb are measured in the MCHC, giving a false 
high value.  RBCs can not have supersaturation of Hb, therefore MCHC is not normally elevated.  
It is possible the increase in MCHC could be due to the hemolysis of RBCs with increased Hb in 
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circulation, and Hz deposition in the RBC and circulation.  MCHC significantly decreased 
during the chronic infection on day 42 PI.   Decreased in MCHC can be due to reticulocytosis, as 
reticulocytes do not have their full Hb component. 
MCH significantly increased on days 2, 15, and 56 PI.  Elevated MCH index is seen with 
increases with hemolysis.  There was no significant change in the average percent change from 
baseline in these parameters in the acute relative to the chronic stages of infection.  The MCV 
was significantly decreased on day 5 (p<0.05) and the decrease was highly significant on days 7 
and 8.  MCV significantly increase on day 15 in the acute infection and significantly decreased 
in the chronic infection on day 56 PI.  The RDW significantly decreased on day 7 in the acute 
infection and significantly increased on days 34, 42, and 56 in the chronic infection.  Increased 
RDW has been shown to be an indicator of increased hemtaopoiesis, and is correlated with the 
degree of macrocytosis (increases MCV) (115).  During the P. coatneyi infection, the increased 
RDW was correlated with MCV (p<0.05), and RDW was correlated with the increase in 
hemtaopoiesis (RBC) (p<0.05).  There was an average increase of 26% in RDW in the acute 
stage, compared with a 36% average increase in the chronic infection.  
Examining the disease severity profiles for each animal individually, M2198 had the 
worst parasitic burden (highest overall parasitemia, and two strongest rebounds in parasitemia), 
yet did not succumb to the most severe anemia during the chronic stage of disease.  M2198 
showed a 38% reduction in Hb (6.9 g/dL) and Hct (21.7%) levels relative to baseline, and a 42% 
reduction in RBC count (2.82 x 106/μL) during the acute infection (Table 6).  During the chronic 
infection, M2198 had a 21% reduction in Hct and Hb, a 26% decrease in RBCs and a 52% 
increase in RDW (21.4% on day 22 PI).   
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Over the duration of the malarial infection, M10800 became the most anemic of all four 
monkeys on day 42 PI during the chronic infection (11 days following a peak parasitemia of 
almost 5%), with a Hb score of 5.9g/dL, Hct of 18.8%, and a RBC count of (2.8 x 106/μL) which 
is a 37-42% reduction in these parameters below baseline for this animal (Table 6).  During the 
acute infection in M10800, there was a 20-23% decrease in red blood Hct, Hb and RBC count.  
M10800 had a 26% decrease (Day 15 – 9.5%) in RDW in the acute infection and a 31% increase 
(Day 42 -16.8%) over baseline in RDW during the chronic infection.    
M11600 had the least evidence of anemia both in the acute and chronic phases of 
infection, with a 14-20% ([Hb] 9.1g/dL and [Hct] 27%, day 10 PI) and a 27% ([Hb] 7.8 g/dL and 
[Hct] 24.6%, day 42 PI) reduction in overall Hb and Hct, respectively.  M11600 controlled its’ 
parasitemia better than the other three animals, having the lowest overall mean in parasite load.  
The RDW in M11600 increased during the acute infection to 32% above baseline (day 15, 
[RDW] 17.5%) and 17% above baseline (day 42, [RDW] 15.5%) during the chronic infection.     
M11799 had the highest parasite burden during the acute infection on day 8 (peak 
parasitemia, 290,160 parasites/μL).  During the acute infection Hb and Hct was lowest at day 10 
PI ([Hb] 7.1g/dL, [Hct] 20.6%) and a 33-37% reduction in over baseline respectively.  RBC 
count was decreased by 36% below baseline in the acute phase of infection.  During the chronic 
stage of disease, M11799 did not become anemic with the lowest Hb (day 42 PI) decreasing only 
to 9.3 g/dL, and Hct to 29%, and RBCs to 3.98 x 106/μL. 
Normal published values for PLT in healthy adult rhesus macaques are 260-361 x 103/μL 
(shown in Table 1) (136).  In all four animals, there was a significant thrombocytopenia (PLT < 
260) during the acute infection on days 2 and 8 PI, and on day 34 PI during the chronic infection 
(Table 7).   
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Table 7: Leukocyte and Platelet Indices in Rhesus Macaques infected with P. coatneyi 
Leukocyte Indices
WBC (x103/mL) D0 D2 D5 D7 D8 D10 D15 D22 D34 D42 D56 D150
M2198 6.8 6.6 4.9* 4.3 5.8 9.1 26 6 9.9 6.8 10 10.4
M10800 6.7 4.6 5.2* 6.2 6.4 9.2 11.2 8.7 9.7 8.4 8.9 28.4
M11600 6.8 5.6 5.9* 5.1 3.5 3.8 6.7 7.1 4.5 5.8 7.7 16.8
M11799 7 5.3 4.3* 3 4.1 4.3 11.7 7.4 7.5 4.8 7.5 6.6
LY (x103/mL) D0 D2 D5 D7 D8 D10 D15 D22 D34 D42 D56 D150
M2198 3.5 1.4* 2.1** 2 1.1* 11.6 11.6 1.8* 2 3.8 5.2* 5.1
M10800 3.3 1.7* 1.8** 3.7 1.8* 6.3 6.3 2* 4.4 4.9 6.7* 24.3
M11600 3.2 2.3* 1.7** 1.9 1* 6.0 6 1.8* 1.5 3.3 4.8* 9
M11799 4.3 1.8* 2.1** 2.1 0.9* 7.0 7 3.9* 1.2 1.9 6* 3.9
MO (x103/mL) D0 D2 D5 D7 D8 D10 D15 D22 D34 D42 D56 D150
M2198 0.5 0.3 0.5 0.4 0.6 0.4 0.1 0.9 0.8 1.2* 0.6 0.4
M10800 0.2 0.1 0.2 0.7 0.5 0.6 0.6 0.4 1.5 1.1* 0.3 0.9
M11600 0.3 0.4 0.1 0.4 0.2 0.3 0.3 0.1 0.5 1.2* 0.2 0.8
M11799 0.6 0.2 0.3 0.4 0.3 0.3 0.2 0.4 0.8 0.8* 0.2 0.6
NEU (x103/mL) D0 D2 D5 D7 D8 D10 D15 D22 D34 D42 D56 D150
M2198 2.5 4.7 2.3 1.8* 4.1 9.1 14 3.3 6.8 1.5 4 4.8
M10800 3.2 2.1 2.8 1.7* 4.1 3.9 3.6 6 3.7 2.2 1.8 3.2
M11600 3.2 2.7 4.1 2.6* 2.3 1.4 0.4 5.2 2.5 1.2 2.5 6.9
M11799 2 3.1 1.8 0.5* 2.7 3.5 4.2 2.4 5.4 2.1 1.3 2
Platlet Indices
Plt (x103/mL) D0 D2 D5 D7 D8 D10 D15 D22 D34 D42 D56 D150
M2198 332 289* 329 375 259* 139 474* 299 270* 282 318 405*
M10800 316 194* 282 257 240* 439.5 639* 216 193* 242 357 387*
M11600 273 156* 281 278 205* 257 703* 211 173* 247 299 288*
M11799 483 377* 462 353 270* 197 584* 520 284* 236 374 520*
MPV (fL) D0 D2 D5 D7 D8 D10 D15 D22 D34 D42 D56 D150
M2198 7.6 7.7 8.6** 8.4* 8 9.3* 9.5 9** 10.2** 10.7* 9* 9.2**
M10800 8.8 8.7 10.3** 10* 10.4 9.3* 9.5 10.1** 11.4** 10* 10* 11.4**
M11600 7.3 7.2 8.5** 8.1* 7.7 8* 7.3 8.2** 8.8** 8.7* 7.6* 8.8**
M11799 6.9 6.5 8.1** 8.6* 8.5 8.9* 9.5 8.6** 8.7** 9.7* 8* 8.7**
* Denotes P<0.05 (by Mann-Whtiney U) relative to baseline levels (Day 0)
** Denotes P<0.01 (by Mann-Whitney U) relative to baseline levels (Day 0)  
Thrombocytopenia was most severe during the acute infection, with a 39-59% reduction 
(mean = 50% reduction) during the acute infection, and 19-51% (mean = 37% reduction) in the 
chronic infection (Table 8).  PLT were significantly elevated on both days 15 and 150 PI.  The 
increase in PLT on day 150 PI may be due to an infection in the animals, as they all had a strong 
inflammatory immune response on this day though parasitemia was cleared.  On day 15 PI 
during the chronic infection, PLT significantly peaked to levels as high as 700, and the increase 
over baseline ranged from 21-158 (mean = 81% increase).   
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Table 8: Leukocyte and Platelet Indices in Acute and Chronic Stages of Malaria (Percent Change 
Relative to Baseline) 
Leukocyte Indices ACUTE CHRONIC ACUTE CHRONIC
(% Decrease) (% Decrease) (% Increase) (% Increase)
WBC
M2198 -37 -12 282 53
M10800 -31 -25 67 324
M11600 -49 -34 0 147
M11799 -57 -31 67 7
AVERAGE -43 -26 104 133
LY
M2198 -69 -49 231 49
M10800 -48 -39 91 636
M11600 -69 -53 88 181
M11799 -79 -72 63 7
AVERAGE -66 -53 118 218
MO
M2198 -80 -20 20 80
M10800 -50 -50 250 650
M11600 -67 -67 33 300
M11799 -67 -67 0 33
AVERAGE -66 -51 76 266
NEU
M2198 -28 -40 460 172
M10800 -47 -44 28 88
M11600 -88 -63 28 116
M11799 -75 -35 110 170
AVERAGE -59 -45 157 136
Platlet Indices ACUTE CHRONIC ACUTE CHRONIC
(% Decrease) (% Decrease) (% Increase) (% Increase)
Plt
M2198 -58 -19 43 22
M10800 -39 -39 102 22
M11600 -43 -37 158 10
M11799 -59 -51 21 8
AVERAGE -50 -36 81 15
MPV
M2198 0 0 25 41
M10800 0 0 18 30
M11600 -1 0 16 21
M11799 -6 0 38 41
AVERAGE -2 0 24 33  
 
During the chronic infection, the mean PLT increase was 15%.  Parasitemia negatively 
correlated with level of PLT (p<0.05, by Pearson correlation) (Figure 7).  PLT were positively 
correlated with both WBC and LY through the course of infection (p<0.05).  PLT were also 
associated with MCV and MCH (p<0.01).   
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Figure 7: Parasitemia and Thrombocytopenia in Rhesus Macaques infected with P. coatneyi 
 
Lowest levels of Hb during the acute infection were correlated with magnitude of PLT rebound 
after thrombocytopenia at parasite clearance (p<0.05) by randomization tests to obtain p-values 
for Pearson correlation (Figure 8).   
MPV was examined as an indicator of PLT production in bone marrow.  MPV in malaria 
is thought to decrease with increasing parasitemia (107).  However, this was contradictory to the 
findings in our study.  MPV was not positively correlated with PLT production, nor negatively 
correlated with increased parasitemia.  There was an average 24% increase in the acute infection 
and 33% mean increase in the chronic infection.  MPV was significantly elevated above baseline 
on days 5, 22, 34, and 150 PI (p<0.01), and was significantly higher on days 7, 10, 42, and 56 PI 
(p<0.05), which encompassed most of the days during the malarial infection.   
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Figure 8: Thrombocytopenia and Anemia in Rhesus Macaques Infected with P. coatneyi 
 
No significant association existed between parasite clearance and rebound in MPV, 
counterbalancing the loss of PLT during parasitemia (Table 9).  MPV was found to be positively 
associated with both Hb and Hct (p<0.01), and negatively associated with both MCV and MCH 
(p<0.01).  Lastly, there was a positive correlation between MPV and MO, LY, and WBC 
(p<0.01).  
Table 9: Correlations among Hematological Parameters during P. coatneyi Malaria 
PARA RBC HB HCT MCV MCH MCHC RDW WBC LY MO NEU PLT MPV TEMP
PARA x -0.0005 -0.0115
RBC x 0.0000 0.0000 -0.0385
HB 0.0000 x 0.0000 -0.0360 -0.0230 -0.0220
HCT 0.0000 0.0000 x -0.0345
MCV -0.0005 x 0.0000 0.0245 0.0000 -0.0095 0.0155
MCH 0.0000 x 0.0020 0.0015 0.0020 -0.0015
MCHC 0.0020 x 0.0075 -0.0405 0.0045
RDW -0.0385 -0.0360 0.0245 0.0075 x 0.0145 0.0210
WBC -0.0405 x 0.0000 0.0000 0.0300 0.0010
LY 0.0000 x 0.0410 0.0130 0.0040 -0.0425
MO -0.0230 0.0015 0.0045 0.0145 x 0.0000
NEU 0.0000 0.0410 x
PLT -0.0115 0.0000 0.0020 0.0300 0.0130 x
MPV -0.0220 -0.0345 -0.0095 -0.0015 0.0010 0.0040 0.0000 x
TEMP 0.0155 0.0210 -0.0425 x  
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WBC, LY and NEU were all positively correlated (p<0.05), and none were associated 
with MO.  WBC were also correlated with MPV (p<0.01), and negatively correlated with MCHC 
(p<0.05).  During the acute infection, there was a significant leukopenia in the four animals just 
prior to peak parasitemia, on day 7 PI (p<0.05).  Leukopenia is common in falciparum malaria in 
non-immune adults and is usually reflective of neutropenia. (116).  As predicted, neutrophils 
were significantly decreased on day 7 PI (p<0.05).  There was a monocytosis on day 22 PI, 
which is seen in falciparum malaria in children and non-immune adults (116).  MO were 
positively associated with MCH (p<0.01), MPV (p<0.01), MCHC (p<0.01) and RDW (p<0.05).  
Hb and monocytes were found to be inversely correlated (p<0.05). LY were positively associated 
with MPV (p<0.01).  There was a significant lymphopenia on days 2 (p<0.05), 5, (p<0.01) 8 
(p<0.05) and 22 (p<0.05) PI, which is seen in acute malaria in the non-immune (116), with a 
lymphocytosis rebound on day 56 PI (p<0.05).  Lymphopenia was found to be correlated with 
body temperature (p<0.05).   
M2198 had a 37% decrease in WBC on day 7 PI of the acute infection (4.3 x 103/μL) and 
then a 282% increase in WBC on day 15 PI (26 x 103/μL), also the day of lowest Hb during the 
acute infection (Table 7).  During the chronic stage of infection, there was a 53% increase in 
WBC during the chronic infection on day 150 (10.4 x 103/μL).  LY were lowest in the acute 
infection on day 8 (peak parasitemia) at 1.1 x 103/μL.  On day 10, when a hyperparasitemia 
occurred, LY increased to 11.6 x 103/μL (231% above baseline) and remained at this level on 
day 15 PI.  During the chronic infection stage, LY dropped to 1.8 x 103/μL on day 22 PO (49% 
reduction) and increased again on day 56 PI to 5.2 x 103/μL (49% increase).  MO decreased by 
80% in the acute phase of infection (day 15 PI, 0.1 x 103/μL) and increased 80 % in the chronic 
stage (day 42 PI, 1.2 x 103/μL) (Table 8).  NEU were significantly lower on day 7 PI, one day 
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prior to peak parasitemia (1.8 x 103/μL).  NEU were elevated to 9.1 x 103/μL and increased by 
460% from baseline in the acute infection (day 15 PI, 14 x 103/μL) and 172% in the chronic 
infection (day 34 PI, 6.8 x 103/μL). 
M10800 had a 31% decrease in WBC on day 2 PI, and then a 67% increase from baseline 
on day 15 PI, with a WBC of 11.2 x 103/μL (Table 7).  During the chronic infection WBC 
increased by 324% on day 150 PI, where they were at 28.4 x 103/μL.  On day 2 PI, M10800 also 
had the lowest level of LY at 1.7 x 103/μL, which was a 48% decrease from baseline.  On days 
10 and 15, LY had increased by 91% above baseline to 6.3 x 103/μL, decreasing on day 22 PI to 
1.8 x 103/μL, a 39% reduction.  On day 150 PI, the animal had a 636% increase in LY to 24.3 x 
103/μL, which follows the increase in WBC.  MO increased by 250% during the acute infection 
(day 7 PI, 0.7 x 103/μL) and by 650% during the chronic infection on day 34 PI to 1.5 x 103/μL.  
NEU were lowest in the acute infection on day 7 PI (1.7 x 103/μL, 47% reduction).  On day 8 PI, 
NEU increased to 4.1 x 103/μL (28% increase), the peaked again on day 22 PI (88% increase, 6 x 
103/μL) (Table 8).  NEU were lowest during the chronic infection on day 56 PI with a 44% 
reduction to 1.8 x 103/μL.  
M11600 had the best control over both parasitic and anemic conditions.  WBC were 
elevated on day 150 PI to 16.8 x 103/μL (147% increase) (Table 7).  WBC were not significantly 
elevated during the other timepoints.  WBC were lowest at peak parasitemia in the acute phase 
(day 8 PI, 3.5 x 103/μL, 57% reduction), and day 34 PI during the chronic infection (4.5 x 
103/μL, 34% reduction).  LY were highest in on day 150 PI (9 x 103/μL, 181% increase), and 
also elevated in day 56 PI (4.8 x 103/μL).  There was a lymphopenia at peak parasitemia during 
the acute infection (day 8, 1 x 103/μL, 69% reduction), and on day 34 in the chronic phase of 
 55 
infection (1.5 x 103/μL, 53% reduction). During the chronic infection on day 42 PI, there was a 
monocytosis at 1.2 x 103/μL (a 300% increase).  MO were lowest on days 5 and 22 PI (0.1 x 
103/μL, 67% reduction).  M11600 had a neutropenia on day 15 PI (0.4 x 103/μL, 88% reduction).  
NEU were highest on day 150 PI, at 6.9 x 103/μL, and also elevated on day 22 PI ay 5.2 x 
103/μL. 
M11799 showed the largest fluctuations in WBC during the acute phase of infection.  
WBC increased on day 15 PI to 11.7 x 103/μL (67% increase) and were lowest on day 7 PI at 3 x 
103/μL (57% decrease) (Table 7).  LY were lowest on day 8 PI (0.9 x 103/μL, a 79% decrease) 
and highest on day 10 and 15 at 7 x 103/μL (63% increase).  MO were highest on days 34 and 56 
PI at 0.8 x 103/μL.  NEU were lowest on day 7 PI at 0.5 x 103/μL (75% decrease) and highest on 
days 15 (4.2 x 103/μL, 110% increase) and 34 PI (5.4 x 103/μL, 170% increase). 
4.2 CYTOKINE AND EFFECTOR MOLECULE PROFILES 
4.2.1 Plasma Cytokine Levels 
Cytokines were measured at each of the eight timepoints for each monkey. Plasma 
cytokine levels at each timepoint, varied among the four animals.  As such cytokine levels were 
examined in the group, and then individual profiles were also addressed.  Plasma levels of IL-12, 
IL-10, TNF-α and NOx were all positively associated (p<0.01 by Pearson correlation) (Table 
10).  However, none of these cytokines were correlated with plasma levels of IFN-γ, released 
from CD4+ T cells.  Associations among IL-12, TNF-α, IL-10 and NOx have been shown in 
human malaria (108), (141).  
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Table 10: Correlation Among Plasma Cytokine Levels during P. coatneyi Malaria 
*Denotes (p<0.05) by 1-tailed randomization-based Pearson correlations 
**Denotes (p<0.01) by 1-tailed randomization-based Pearson correlations
XX(0.008)**0.426(0.002)**0.498(0.170)0.174<0.001**0.679NO
(0.008)**0.426XX<0.001**0.585(0.185)0.164(0.001)**0.567IL-10
(0.002)**0.498<0.001**0.585XX(0.213)0.146(0.001)**0.543TNF-α
0.1700.1740.1850.1640.2130.146XX(0.058)   0.284IFN-γ
<0.001**0.679(0.001)**0.567(0.001)**0.543(0.058)0.284XXIL-12
(p-value)r(p-value)r(p-value)r(p-value)r(p-value)r
NOIL-10TNF-αIFN-γIL-12PLASMA LEVELS
Pearson Correlations Among Plasma Cytokine & Effector Molecule 
 
Plasma cytokine levels at each timepoint were compared relative to baseline for 
significance using a Mann-Whitney U test.  (Table 11)  IFN-γ plasma levels were significantly 
elevated above baseline in all four animals on day 22 PI (p<0.05).  IL-12p40 cytokine levels 
were not significantly augmented above baseline at any timepoints in all four animals.  TNF-α 
plasma levels were significantly augmented on day 8 PI (peak parasitemia).  Plasma levels of 
NOx were significantly elevated on day 2 PI.  Plasma levels of anti-inflammatory IL-10 were 
significantly elevated above baseline on days 5 and 7 PI in all four animals. (p<0.05) 
Table 11: Plasma Cytokine Levels Relative to Baseline 
p-values
Plasma D2 D5 D7 D8 D10 D15 D22
IFN-γ 0.262 0.071 0.249 0.166 0.053 0.053 0.014**
IL-12p40 0.209 0.109 0.063 0.160 0.192 0.110 0.259
TNF-α 0.389 0.989 0.382 0.013* 0.072 0.072 0.081
IL-10 0.136 0.007* 0.022* 0.100 0.130 0.081 0.131
NO 0.038* 0.082 0.225 0.255 0.053 0.420 0.070
* Denotes P<0.05 (by Mann-Whitney U) relative to baseline levels (Day 0)
** Denotes P<0.01 (by Mann-Whitney U) relative to baseline levels (Day 0)  
Plasma levels of IL-12 were shown as percent change relative to baseline (Figure 9).  IL-
12 plasma levels in the four animals were positively associated with parasitemia (p<0.01 by 
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Pearson correlation).  The degree of peak parasitemia on day 8 PI was predicted by plasma levels 
of IL-12 on day 5 PI (p<0.05).   
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Figure 9: Plasma IL-12 Relative to Parasitemia during P. coatneyi Malaria 
 
M2198 had the highest IL-12 response of all four animals, increasing 573-733% above baseline 
on days with high parasite burden (Figure 10).  Plasma IL-12 levels increased with increasing 
parasitemia in M2198 and were highest on days 8 (peak parasitemia), 10 (hyperparasitemia), and 
22 PI (re-emergence of parasites).  In M10800, levels of IL-12 were highest on day 7 (273% 
increase), one day prior to peak parasitemia.  IL-12 plasma levels decreased with clearance of 
parasitemia and increased with the re-emergence of parasites on day 22 PI (137% increase).  
M11600 showed a reduction in plasma levels of IL-12 on days 2, 5, 8, and 15 PI.  Plasma IL-12 
levels increased slightly on days 7 and 10 PI in M11600 (29% increase).  M11799 had a high IL-
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12 response at peak parasitemia (day 8 PI, 296% increase).  IL-12 response did not increase 
significantly on day 22 PI with the re-emergence of parasitemia (11% increase). 
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Figure 10: Magnitude of Plasma Cytokine Response during Malaria 
 
Plasma IFN-γ levels in the four animals were shown to be positively correlated with 
parasitemia (p<0.05) (Figure 11).  Plasma IFN-γ response in M2198 increased with parasitemia 
on days 8 (peak parasitemia, 302%) and 10 PI (hyperparasitemia, 388%), then decreased on day 
15 PI, when parasitemia had cleared (32% increase). Plasma levels increased on day 22 PI with 
the re-emergence of parasitemia (339 % above baseline) (Figure 10).  M10800 had a decrease in 
plasma IFN-γ levels below baseline on days 2 and 7 PI.  Plasma levels of IFN-γ increased 
dramatically in M10800 at peak parasitemia (1106% on day 8 PI), and remained elevated at day 
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10 PI (626% above baseline).  Plasma IFN-γ levels in M10800 were similar on days 15 and 22, 
with 146 and 125% increase respectively.  IFN-γ plasma levels in M11600 were highest on days 
7 (177% increase), 10 (157% increase) and 22 PI (262 % increase).  Plasma IFN-γ levels in 
M11799 were highest on day 7 PI (568%) and on parasite clearance, day 15 PI (233%). 
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Figure 11: Plasma IFN-γ Levels Relative to Parasitemia 
 
Plasma TNF-α levels were positively correlated with parasitemia in all four animas 
(p<0.01).  (Figure 12).  TNF-α plasma levels on day 7 PI were a negative predictor of peak 
parasitemia on day 8 PI (p<0.05, Pearson).  Plasma TNF-α in M2198 was highest at peak 
parasitemia (124% increase) and hyperparasitemia on day 10 PI (99% increase), and decreased 
below baseline on days 7 PI and day 15 PI, just prior to increases in parasitemia.  M10800 had an 
elevated plasma TNF-α  response on days 7, 8, and 10 PI (>150% increases above baseline).  At 
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parasite clearance on day 15 PI, TNF-α plasma levels remained elevated (120% above baseline, 
and then declined at the re-emergence of parasitemia on day 22 PI (66% increase over baseline).  
M11600 had a decrease in plasma TNF-α levels on days 2, 5 and 15 PI, following the same 
trends as plasma IL-12 reduction.  TNF-α plasma levels were highest at peak parasitemia in 
M11600 (49% increase above baseline).  M11799 had low plasma levels of TNF-α relative to 
baseline on days 2, 5, and 7 PI.  Plasma TNF-α levels in M11799 were highest at parasite 
clearance, day 15 PI (146% increase) and at peak parasitemia, day 8 PI (121% increase).   
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Figure 12: Plasma Levels of TNF-α Relative to Parasitemia 
 
Parasitemia and plasma levels of IL-10 were positively correlated in the four animals 
(p<0.01) (Figure13).  Plasma IL-10 levels in M2198 increased with parasitemia, and were 
highest on peak parasitemia (3162% increase) and hyperparasitemia day 10 (1662% increase).  
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Levels of IL-10 decreased at parasite clearance (369% increase from baseline) and increased 
with the re-occurrence of parasites on day 22 PI (763% increase) (Figure 10).  Plasma levels of 
IL-10 followed parasitemia in M10800, and increased to 733% above baseline on day 5 PI, and 
then decreased to 276% on day 7 PI, when parasitemia decreased.  In M10800, plasma IL-10 
levels increased to 988% above baseline at peak parasitemia, decreased to 169% at parasite 
clearance, and then increase to 732% at the re-occurrence of parasites on day 22 PI (Figure 10).  
M11600 had high plasma IL-10 levels on day 5 PI (2740% increase) and peak parasitemia 
(4930% increase).  Plasma IL-10 levels decreased at parasite clearance on day 15 PI (107%) and 
rebounded (237% above baseline) on day 22 PI when parasitemia increased.  M11799 had 
increased plasma IL-10 levels at peak parasitemia (12046% increase), and decreased plasma IL-
10 levels as parasitemia decreased.  Plasma IL-10 levels in M11799 did not increase significantly 
as parasitemia re-emerged on day 22 PI (155% increase).   
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Figure 13: Plasma Levels of IL-10 Relative to Parasitemia 
 
4.2.2 Effector Molecule Profiles 
Parasitemia was positively correlated with NOx plasma levels in all four animals (p<0.01 
by Pearson correlation) (Figure 14).  NOx plasma levels increased with parasitemia and were 
elevated during peak parasitemia (112% increase) and hyperparasitemia (117% increase) in 
M2198.  Levels of NOx did not increase significantly in M2198 with the reemergence of 
parasites on day 22 PI (16% increase).  NOx plasma levels in M10800 did not follow trends in 
parasitemia.  Plasma NOx levels were highest on day 2, 5, 8, 10, and 22 PI (47-57% increases).  
Levels of plasma NOx in M11600 were highest on days 2, 7, and 10 PI (34-36% increases).  
NOx plasma levels declined in M11600 at parasite clearance on day 15 PI and were at 24% 
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below baseline.  Plasma levels of NOx in M11799 did not follow trends in parasite burden.  
M11799 had the highest plasma NOx levels on day 2 PI (72% increase) and on days 8, 10 and 15 
PI (38-43% increases).   
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Figure 14: Plasma NOx Levels Relative to Parasitemia 
 
4.2.3 Transcript Profiles 
To determine if plasma cytokine levels were regulated at the transcriptional level in 
PBMC, transcript levels of each cytokine were measured at each of the eight timepoints.  
Pearson correlation was performed to determine if there was an association between plasma 
cytokine levels and PBMC transcripts.  IL-12 transcript levels significantly decreased on days 10 
(p<0.05), 15 (p<0.05), and 22 PI (p<0.01).  IFN-γ transcript levels significantly increased above 
baseline on days 2 (p<0.01), 5 (p<0.05), and 7 (p<0.05), 10 (p<0.01), and 15 PI (p<0.01) (Table 
12).   
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Table 12: Statistical Significance of Cytokine Transcript Levels Relative to Baseline 
p-values
Transcripts D2 D5 D7 D8 D10 D15 D22
IFN-γ 0.0003** 0.016* 0.018* 0.000** 0.000** 0.000** 0.202
IL-12p40 0.296 0.235 0.173 0.856 0.007* 0.033* 0.001**
TNF-α 0.378 0.305 0.281 0.039* 0.263 0.024* 0.121
IL-10 0.320 0.324 0.195 0.339 0.252 0.432 0.833
* Denotes P<0.05 (by Mann-Whitney U) relative to baseline levels (Day 0)
** Denotes P<0.01 (by Mann-Whitney U) relative to baseline levels (Day 0)  
TNF-α transcript levels were significantly elevated on days 8 (p<0.05) and 15 PI (p<0.05).  IL-
10 transcript levels were not significantly elevated over baseline at any of the timepoints during 
the study.  Due to the variation among animals and the small sample size, transcript profiles were 
examined in each monkey, and compared to plasma levels.  IL-12 transcripts were positively 
correlated with IFN-γ transcripts (p<0.05), which were positively correlated with TNF-α 
transcripts (p<0.05), which were positively correlated with IL-10 transcripts (p<0.01) (Table 13).  
This coincides with the mechanism of regulation, where IL-12 induced protection in malaria is 
related to the ability of IL-12 to promote secretion of IFN-γ from Th1 cells.  IFN-γ stimulates 
monocytes to release TNF-α that can induce cytotoxic free radicals, such as NO (60). 
Table 13: Correlation Among Cytokine Transcripts during P. coatneyi Malaria 
*Denotes (p<0.05) by 1-tailed randomization-based Pearson correlations 
**Denotes (p<0.01) by 1-tailed randomization-based Pearson correlations
XX<0.001**0.592(0.310)0.091(0.493)-0.003IL-10
<0.001**0.592XX(0.382)-0.055(0.356)-0.068TNF-α
(0.310)0.0910.382-0.055XX(0.018)*0.371IFN-γ
(0.493)-0.0030.356-0.068(0.018)*0.371XXIL-12
(p-value)r(p-value)r(p-value)r(p-value)r
IL-10TNF-αIFN-γIL-12TRANSCRIPTS
Pearson Correlations Among Cytokine Transcripts
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IL-12 increased in the early infection as parasitemia began to increase (Figure 15).  
M2198 had a 2-fold increase on days 5 and 7, and then transcript levels decreased at peak 
parasitemia, and remained relatively unchanged for the other timepoints.  M10800 had high 
levels on days 2 (4-fold increase), 5(10-fold increase), and 7 (6-fold increase) PI.  M11600 had 
an increase in IL-12 transcripts on days 2 (3-fold), 5 (4-fold), 7 (9-fold) and 8 (4-fold) PI.  IL-12 
transcript levels M11799 showed little fluctuation during the entire infection.  Plasma levels of 
IL-12 were not significantly associated with transcript levels in any of the animals, suggesting 
that plasma levels of IL-12 are from other sources than solely PBMC.     
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Figure 15: IL-12p40 Transcript Levels Relative to Parasitemia 
 
M2198 had a 2-fold increase in IFN-γ  on day 5, followed by a 6-fold IFN-γ increase on 
day 10 PI (Figure 16).  M10800 showed a 2-fold increase in IFN-γ early in the infection on days 
2 and 5, and little IFN-γ transcription activity on any other days.   In M11600, there was a strong 
early IFN-γ transcription on days 2 and 5 PI (above a 10-fold increase), followed by a 4-fold 
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increase on day 7 PI and 2-fold increase on day 15 PI.  M11799 did not have much fluctuation in 
IFN-γ transcription.  IFN-γ transcript and plasma levels were not correlated by regression 
analysis, demonstrating that plasma IFN-γ is not solely derived from PBMC in rhesus infected 
with P. coatneyi.   
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Figure 16: IFN-γ Transcript Levels Relative to Parasitemia 
 
There was a strong increase in TNF-α transcription after peak parasitemia (Figure 17).  
M2198 had increasing TNF-α levels with the initial peak in parasitemia, where they increased 2-
fold on day 8, and 3-fold on day 10 PI.  M10800 had the highest TNF-α response, which 
increased with initial peak parasitemia, and elevated through day 15 (9-fold increase) until day 
22, where levels dropped to 7-fold increase.  TNF-α transcripts in M11600 increased 5-fold at 
peak parasitemia, increased 10-fold at parasite clearance on day 15, and then decreased to 5-fold 
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on day 22 PI.  In animal M11799, TNF-α transcripts increased 3-fold at peak parasitemia, and 
then increased 5-fold at re-emergence of parasitemia on day 22 PI.  TNF-α transcript and plasma 
levels were not correlated in any of the four animals.  
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Figure 17: TNF-α Transcript Levels Relative to Parasitemia 
 
IL-10 transcripts did not fluctuate in the four animals with the exception of M11600, 
which had an increase in IL-10 transcription in day 7, 8 and 15 (12-fold increase) and 22.  
(Figure18).   M11799 also had an increase in IL-10 transcripts at the re-emergence of parasitemia 
on day 22 PI (4-fold increase).  Plasma levels of IL-10 did not follow transcript levels in any of 
the animals and therefore plasma IL-10 not likely from PBMC.     
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Figure 18: IL-10 Transcript Levels Relative to Parasitemia 
4.3 CORRELATION OF CYTOKINE LEVELS WITH HEMATOLOGICAL 
OUTCOMES 
Both plasma cytokine and transcript cytokine levels were compared to Hb and Hct to 
determine in there was a correlation between pro- and anti-inflammatory cytokine production 
and transcription as predictors of anemia.  Randomization tests to determine p-values for 
Pearson-correlations were performed at each timepoint, and also compared variables at different 
timepoints to determine if there was a correlation between anemia and cytokine production.  
Small sample size accompanied by the level of variation among the four animals made it difficult 
to model and achieve significance.     
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4.3.1 Cytokine and Effector Molecule Regulation during Anemia 
IL-12 transcript levels were positively correlated with Hb and Hct and RBCs (p<0.05), 
which supports that IL-12 does play a protective role in malarial anemia in a P. coatneyi 
infection in rhesus macaques, just as it does in human malaria (32), (142) (Table 14).  IL-12 may 
play a protective role in coatneyi malaria through PLT (106).   
Table 14: Correlation Among Plasma Cytokine Levels and Clinical Parameters of Disease Severity in 
P. coatneyi Malaria 
*Denotes (p<0.05) by 1-tailed randomization-based Pearson correlations 
**Denotes (p<0.01) by 1-tailed randomization-based Pearson correlations
(0.056)-0.287(0.104)-0.229(0.313)-0.089(0.283)-0.105(0.605)-0.280PLATELETS
(0.213)-0.146(0.155)-0.185(0.061)-0.279(0.034)*-0.328(0.104)-0.229HCT
(0.340)-0.076(0.227)-0.137(0.126)-0.209(0.044)*-0.307(0.177)-0.169HB
(0.001)**0.561(0.000)**0.759(0.000)**0.605(0.012)*0.399(0.000)**0.612PARASITEMIA
(p-value)r(p-value)r(p-value)r(p-value)r(p-value)r
NOIL-10TNF-αIFN-γIL-12PLASMA LEVELS
Pearson Correlations Among Plasma Cytokine & Effector Molecule and Clinical 
Parameters of Disease Severity
 
Animals that had a lower Hb in the acute infection had increased IL-12 plasma levels 
during the higher levels of parasitemia (Figure 19).  At peak parasitemia (day 8 PI), plasma 
levels of IL-12 followed the decrease in Hb until day 15 PI, when both increased through day 22 
PI.  IL-12 transcripts on days 7 and 8 PI were positive predictors of anemia during the acute 
infection (p<0.05).  M2198 had the lowest Hb during the acute infection and also the highest 
levels of IL-12.  Animals that had the least change in Hb during the acute phase of disease had 
the highest increase in IL-12 transcript levels in the early infection on days 2, 5, 7 PI (M10800, 
M11600).  M2198 and M11799 had the lowest Hb levels in the acute phase of infection with a 
low level of IL-12 transcription in the early infection.   
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Figure 19: IL-12 (Plasma and Transcript Levels) Relative to Anemia 
 
IFN-γ transcript levels were positively correlated with Hb, Hct and RBC counts and IL-
12 transcript levels, implicating that IL-12 induced IFN-γ could play a protective role in anemia 
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(Table 14).  Both plasma levels of IFN-γ and Hb decrease at parasite clearance (day 15 PI) 
(Figure 20) and increase with the reoccurrence of parasites on day 22 PI, though results were not 
significant.  Plasma levels of IFN-γ on day 10 PI were positively correlated with level of Hb on 
day 42 PI (p<0.05) (Figure 20).  The degree of Hb loss during day 42 in the acute infection was 
in part predicted by the level of IFN-γ response during day 10 in the acute infection (p<0.05).  
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Figure 20: IFN-γ (Plasma and Transcript Levels) Relative to Anemia 
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TNF-α levels in plasma increased at peak parasitemia and decreased with the decline in 
Hb, with the exception of M11799, increased on day 15 PI.  Transcript levels of TNF-α were 
highest in animals that were able to control anemia during the acute phase of infection (M10800, 
M11600) (Figure 21).  TNF-α transcripts were highest in these animals at peak parasitemia and 
parasite clearance.  TNF-α transcript levels at levels on day 15 PI were significantly associated 
with level of Hb decline (p<0.05) by Pearson-correlation. 
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Figure 21: TNF-α (Plasma and Transcript Levels) Relative to Anemia 
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IL-10 plasma levels were highest at peak parasitemia, and correlated negatively with 
level of Hb (Figure 21).  Higher plasma level of IL-10 on day 7 PI correlated with the lowest Hb 
levels (p<0.05).  Transcript levels of IL-10 were highest following parasite clearance, and were 
higher in the animals that had elevated Hb during the acute phase of infection (M10800 and 
M11600).  Increased IL-10 transcripts at parasite clearance (day 15 PI) were significantly 
associated with having a less severe anemia (p<0.05).   
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Figure 22: IL-10 (Plasma and Transcript Levels) Relative to Anemia 
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Plasma levels of total NO were highest in the animal that had the lowest Hb in the acute 
infection (M2198) at peak parasitemia and hyperparasitemia (Figure 23). Transcript levels of NO 
were undetectable by real time RT-PCR.  Levels of NO production were not associated with Hb 
in all four animals. 
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Figure 23: NOx (Plasma Levels) Relative to Anemia 
 
4.3.2 Regulation of Platelets 
Although thrombocytopenia can be harmful, having a reduced PLT count during 
falciparum malaria has also been shown to be protective as it reduces parasite sequestration 
(106).  IL-12 transcripts were negatively correlated with PLT levels during the malarial infection 
(p<0.05).  High plasma levels of IL-12 at peak parasitemia on day 8, were significantly inversely 
associated with PLT levels at parasite clearance on day 15 (p<0.05) (Figure 24).  M11600 and 
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M10800 had the highest early levels of IL-12 transcription and had the highest levels of PLT 
production at parasite clearance.  
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Figure 24: IL-12 (Plasma and Transcript Levels) Relative to Thrombocytopenia 
 
PLT followed inverse trends with plasma IFN-γ levels during the malarial infection, but 
were not statistically significant (Figure 25).  Early IFN-γ transcript levels were highest in the 
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animals that had the highest levels of PLT at parasite clearance, but again, there was no statistical 
correlation.   
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Figure 25: IFN-γ (Plasma and Transcript Levels) Relative to Thrombocytopenia 
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Through the course of infection, PLT decreased as TNF-α plasma levels increased 
(Figure 26).  Plasma TNF-α levels prior to peak parasitemia on day 7 PI were significantly 
correlated with high levels of PLT production at parasite clearance on day 15 PI (p<0.05).  TNF-
α transcription was highest at parasite clearance in the animals that produced the highest levels 
of PLT.  High levels of TNF-α at peak parasitemia on day 8 PI corresponded significantly with 
high levels of PLT production at parasite clearance on day 15 PI (p<0.05). 
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Figure 26: TNF-α (Plasma and Transcript Levels) Relative to Thrombocytopenia 
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PLT levels were found to be positively associated with IL-10 transcripts (p<0.01).  
Levels of plasma IL-10 were lowest at parasite clearance, which is when PLT were highest 
(Figure 27).  There was a significant correlation between higher IL-10 plasma levels and lower 
PLT production at parasite clearance (p<0.05).  Transcript levels of IL-10 were highest in 
M11600, which had the highest level of PLT at parasite clearance and the lowest level of PLT at 
the onset of parasitemia (day 2 PI), though these results were not significantly correlated. 
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Figure 27: IL-10 (Plasma and Transcript Levels) Relative to Thrombocytopenia 
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The ability to produce highest levels of NO during acute malaria was highly significantly 
associated with high PLT levels at parasite clearance (p<0.01) (Figure 28).  Transcript levels of 
NO were undetectable by real time RT-PCR.  Production of high plasma levels of NO at peak 
parasitemia were significantly correlated with high PLT at parasite clearance (p<0.05). 
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Figure 28: Plasma NOx Levels Relative to Thrombocytopenia 
 
4.3.3 Anti-/Pro-Inflammatory Cytokine Profiles during Hyperparasitemia and Anemia 
Plasma ratios of anti-inflammatory and pro-inflammatory cytokines were examined at 
levels of peak parasitemia, anemia and highest and lowest PLT levels.  Statistical significance 
was determined using Mann-Whitney U tests (95% Confidence Interval) among the different 
conditions, and randomization tests to compute p-values for Pearson-correlations were used to 
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determine significance between ratios and markers of diseases severity (parasitemia, anemia, 
PLT production).  
During the acute infection, M2198 and M11799 had the most severe parasitemias and 
anemias.  M11600 and M10800 were able to control the degree of anemia in the acute infection.  
Interestingly, both animals had the quickest resolution of parasitemia in the acute infection (day 
15 PI) and the highest level of PLT.  For the duration of this study, M11600 had the least severe 
disease.  In addition, this M11600 presented with the lowest anti-/pro-inflammatory cytokine 
ratios overall (Table 15). 
Table 15: Plasma Cytokine Ratios during Peak Parasitemia, Anemia and Thrombocytopenia 
Baseline
[Hb] IL-10/TNF−α IL-10/IL-12 IL-10/IFN-γ IL-10/NOx
M2198 10.6 0.19 0.15 0.17 0.95
M10800 9.2 0.42 0.14 0.09 0.85
M11600 10 0.02 0.02 0.02 0.11
M11799 8.8 0.10 0.08 0.08 0.42
Peak Parasitemia
[PARA] IL-10/TNF−α IL-10/IL-12 IL-10/IFN-γ IL-10/NOx
M2198 286,590 2.58* 0.57* 1.31* 10.25*
M10800 274,000 1.57* 0.48* 1.31* 6.11*
M11600 236,320 1.13* 1.88* 0.60* 6.97*
M11799 290,160 5.47* 2.43* 3.55* 36.76*
Lowest Hemoglobin
[Hb] IL-10/TNF−α IL-10/IL-12 IL-10/IFN-γ IL-10/NOx
M2198 6.9 1.60 0.33** 0.60** 7.43
M10800 8.2 1.12 0.40** 0.11** 3.94
M11600 9.1 0.06 0.06** 0.02** 0.39
M11799 7.1 0.23 0.34** 0.14** 1.72
Lowetst Platelets
[PLT] IL-10/TNF−α IL-10/IL-12 IL-10/IFN-γ IL-10/NOx
M2198 139 1.60 0.33 0.60 7.43
M10800 194 0.26 0.10 0.09 0.47
M11600 156 0.01 0.01 0.00 0.03
M11799 197 0.69 0.29 0.29 3.12
*Denotes P<0.05 by Mann-Whitney U relative to baseline
**Denotes P<0.05 by Mann-Whitney U relative to peak parasitemia  
Plasma levels of IL-10/TNF-α were not significantly associated with Hb levels at peak 
parasitemia, nor were they significantly associated with lowest Hb levels (anemia).  However, 
plasma levels of IL-10/TNF-α decreased in each animal by at least 40% (and up to>2,000%) in 
all four animals from peak parasitemia, to the day in the acute infection that the animal had the 
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lowest Hb.  Low IL-10/TNF-α level when PLT were lowest was significantly associated with the 
magnitude of PLT increase at parasite clearance (p<0.01).      
Levels of IL-10/IL-12 were significantly lower at anemia than at peak parasitemia 
(p<0.05).  Levels of IL-10/IL-12 were significantly lower when PLT counts peaked and were 
lowest, than at parasite clearance than at peak parasitemia (p<0.05).  When levels of peak PLT 
were compared to cytokine ratios, IL-10/IL-12 levels were significantly associated with highest 
levels of PLT (p<0.05, Pearson).   
IL-10/IFN-γ were significantly lower at acute anemia than at peak parasitemia (p<0.05) 
Levels of IL-10/IFN-γ were significantly lower when PLT were highest, than at parasite 
clearance than at peak parasitemia (p<0.05).  Levels of peak PLT were compared to cytokine 
ratios and it was determined that IL-10/IFN-γ levels were significantly associated with highest 
levels of PLT (p<0.05, Pearson).   
Lastly, levels of IL-10/NOx were examined at peak parasitemia, anemia, and highest and 
lowest PLT.  There was a significant decrease in the IL-10/NOx ratios from peak parasitemia to 
parasite clearance, which is the same day PLT peaked (p<0.05).  Increased levels of PLT on 
parasite clearance (day 15 PI) correlated with low levels of IL-10/NOx (p<0.05).   
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5.0  DISCUSSION 
P. coatneyi infection in rhesus macaques represents a valid model system for 
investigating malarial anemia.  Cytokines are key determinants of malaria severity and outcome 
(143), (33) (144), (145), (35), (146), (147) and are potential targets for therapeutic interventions 
if their effects can be better understood.  The balance between pro-and anti-inflammatory 
cytokines can determine the degree of malaria parasitemia the level of anemia, the clinical 
severity and disease outcome.  Cytokine production and regulation in P. coatneyi-infected rhesus 
macaques are similar to those observed in children with malaria anemia.  In addition, a 
characteristic of malarial infection is the effect of parasitemia on vital immune response 
parameters.  The present study underlies pathophysiological effects of malaria in the rhesus 
macaque model.  As such, parameters of infection determined during malarial infection in rhesus 
were consistent with that observed in humans.  This study is the first to examine vital parameters 
associated with anemia implicated during malaria pathogenesis in the rhesus macaque model.   
5.1 EFFECT OF P. COATNEYI-INFECTION ON HEMATOLOGICAL INDICES – 
ACUTE RELATIVE TO CHRONIC INFECTIONS 
Plasmodium coatneyi infection in rhesus macaques includes clinical symptoms such as 
jaundice, anorexia, listlessness, fever, anemia, and splenomegally (130).  During the course of 
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the malarial infection, fever occurred on days of peak parasitemia, but the overall burden of 
parasitemia did not determine the highest increase in body temperature.  Fever was reduced in 
M2198 at hyperparasitemia, which could be a result of treatment with anti-malarials at peak 
parasitemia.  As expected, body temperature decreased to normal range post-treatments and upon 
parasite clearance.  The largest decline of weight loss occurred in the chronic phase of infection.  
The two animals that had the highest parasite burdens during the infection, M2198 and M11799 
also had the largest decline in body weight during the chronic infection at 17% and 12% 
respectively.  This is a critical maker of disease progression in monkey model systems; in that 
regulations require that if the animal is assessed at 20% weight loss in a study, this is possible 
grounds for early termination.   
Reference values for Hb and Hct vary, and there is no standard definition of malarial 
anemia in rhesus macaques. Therefore, in this study, we defined malarial anemia as Hb 
concentration two standard deviations below the mean.  The mean was derived from baseline 
values for the four animals, as their baseline Hb levels fell below the single source of “normal” 
published values (136).  Anemia associated with malaria is complex, not resulting from a single 
source, and there is a wide spectrum of clinical manifestations.  As such, we attempted to 
characterize the immune response in these animals relative to important markers of malaria 
pathogenesis seen in humans.   
We have shown that Hb scores began to decrease after peak parasitemia and were at 
lowest levels at 1 week post-parasitemia.  After the destruction of RBC by the parasite and/or the 
spleen, the decrease in Hb is also one of the hallmarks in malarial anemia cause by P. falciparum 
in humans.  The decrease in Hb and Hct could be due to the decline in parasitemia post-
treatment, or from the destruction of uninfected RBCs (43).  Hb, Hct, and RBC count, levels 
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significantly increased above baseline (p<0.01) in all four animals on day 5 PI, when parasitemia 
values increased exponentially.  High plasma levels of pro-inflammatory cytokines that would 
suppress hemtaopoiesis did not peak until after this timepoint. At peak parasitemia, Hct, Hb and 
RBCs were significantly decreasing and continued though the acute infection to parasite 
clearance.   Levels increased during the chronic infection, though not to baseline levels, and 
decreased again at the second onset of parasitemia.  During falciparum malaria, there is a 
decrease in Hb after treatment of acute infection, that has been shown to correlate with the level 
of parasitemia when the patient was admitted to the hospital (91).  Likewise, we found that 
during the acute infection, day 8 PI parasitemia was a significant predictor of Hb on day 15 PI.  
However, this was not the case during the chronic infection, where peaks in parasitemia did not 
significantly predict the subsequent decrease in Hb.  Peripheral parasitemia can underestimate 
parasite burden due to parasite sequestration (89), which could explain why the relationship 
between level of parasitemia and degree of anemia are not always correlated during malaria.   
The MCV significantly decreased as parasitemia began to increase in the acute infection, 
indicating a microcytosis (p<0.05).  However, when the animals were the most anemic (lowest 
Hb) in the acute infection, they demonstrated a high MCV but with a decrease in MCHC 
(hypochromia).  This clinical profile is typical of a highly regenerative anemia, where increased 
number of reticulocytes with low Hb concentration will bring down MCHC.  Regenerative 
anemia would be more probable during an acute malarial anemia rather than in chronic anemia.  
As well, the RDW significantly decreased on day 7 PI during the acute infection.  Low RDW 
signifies a normal, homogeneous population of cells, and can also be used as a marker of release 
of early erythrocytes and reticulocytes.  During the chronic infection RDW significantly 
increased on days 34, 42, and 56.  Increased RDW signifies active hemtaopoiesis due to large 
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immature red cells and has been correlated in malaria with the degree of macrocytosis (114), but 
were not significantly associated in this study.   
Thrombocytopenia is a decreased production of PLT, though the mechanism during 
malaria is unclear (104).  Thrombocytopenia may due to suppression of erythropoiesis by pro-
inflammatory cytokine oversecretion (104).  Acute infections in non-immune people present in 
mild to moderate thrombocytopenia, less frequent in immune and semi-immune populations 
(117).  In all four animals, PLT counts significantly decreased during the acute infection.  
Highest levels of PLT on day 15 PI were positively correlated with lowest Hb levels during the 
acute infection (p<0.05).  PLT have also been shown to be a factor in pathogenesis of malaria 
(105), and have been shown to aggregate with parasitized RBCs, impairing circulation and 
increasing sequestration even further (106).  At the timepoint when Hb was lowest during the 
acute infection, PLT counts were highest.  This is possibly due to the compensation for loss of 
RBC, as RBC and PLT both originate from the same hematopoietic progenitor cells.  An 
increased MPV occurs when increased numbers of PLT are being produced.  At levels of highest 
PLT production MPV was highest as well.  Both PLT and MPV decrease with increasing 
parasitemia, and after parasite clearance, increased significantly to counterbalance the loss 
during parasitemia.  This profile is similar to what has been demonstrated in Aotus monkeys 
infected with falciparum malaria (107).  Leukopenia during acute falciparum malaria. is 
common in non-immune adults.  The infiltration of leukocytes was highest at peak parasitemia 
which may subsequently induce dysregulation of other immune parameters leading to an 
exacerbation of disease. 
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5.2 CYTOKINE AND EFFECTOR MOLECULE PROFILES 
The regulation of cytokine profiles during malaria in rhesus was similar to that in humans 
(141), (124), (122).  The timing, degree and balance of the cytokine response has been associated 
with clinical outcomes of disease severity in malaria (26), (141), (148), (29).   The protective 
immune response to malaria is associated with alterations in pro- and anti-inflammatory 
cytokines that may determine disease severity by regulating NO production from blood 
mononuclear cells.   Results presented here show that circulating levels of IL-12, IFN-γ, TNF-α, 
IL-10 and NO increased with disease severity and were positively correlated with parasitemia.  
NO in plasma increased with disease severity and was correlated with circulating levels of TNF-
α and IL-10.  In contrast, plasma NO was inversely correlated with IFN-γ.  Plasma levels of IL-
12 (day 5 PI) and TNF-α (day 7 PI) in the days prior to a peak parasitemia, were positive 
indicators of parasite burden at peak parasitemia.  High levels of immune complexes have been 
documented in severe falciparum malaria (149).  The magnitude of plasma cytokine response 
was greatest in IL-10, with up to 5000% increase over baseline at peak parasitemia.  Pro-
inflammatory IL-12 and IFN-γ were also considerably increased over the course of infection.   
IL-12 transcripts were highest in the early infection at the occurrence of parasitemia and 
at the approach of peak parasitemia.  In malaria, IL-12 is an important initiator of the 
inflammatory cascade, activating monocytes-macrophages (28).  In three of the four animals, 
plasma levels of IL-12 were highest when close to or on the days when parasite burden was very 
high.  The animal with the least severe disease had reduced plasma levels of IL-12 on days 2, 5, 
8, and 15 PI, but also had high levels of IL-12 transcripts in the early acute infection.  Plasma 
IFN-γ levels increased with increasing parasitemia, and were significantly elevated above 
baseline in all four animals when parasites reoccurred on day 22 PI.  Transcript levels also were 
 87 
highest at higher parasitemias.  TNF-α levels were significantly augmented with peak 
parasitemia.  Cytokine levels showed considerable variation in the four animals on each of the 
different timepoints, making it difficult to show significant correlations.  The cytokine profiles 
from this study indicate that the rhesus model is similar to those observed in humans (26), (150), 
(56), (151), (141).  The results of this study reveal differences in transcriptional response of 
cytokines during malaria infection.  PBMC transcript levels did not correlate with plasma levels 
of cytokines, suggesting that the cytokines might be from different sources other than solely 
circulating monocyte-macrophages, such as spleenic macrophages and lymphocytes. 
In the present studies, we have shown that rhesus macaques infected with malaria cause 
an enhanced dysregulation of cytokine production.  Differential expression of IFN-γ and IL-10 
correlated with peak parasitemia.  This is consistent with previous reports which indicate a 
significant inverse relationship between production of IFN-γ and IL-10 with respect to enhanced 
disease severity during malaria (152).  Additionally, over-production of TNF-α is associated 
with promotion of anemia in a variety of chronic and acute inflammatory diseases (45), (44).  
Therefore, since pro-inflammatory responses are implicated in malaria pathogenesis, we have 
shown that the production of TNF-α transcripts correlated with enhanced disease severity, while 
IL-12 transcripts were relatively low and were suppressed with disease progression.  Taken 
together, the data presented here elucidates the response of plasma cytokines during malaria 
infection at whereby peak parasitemia is associated with enhanced production. 
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5.3 CORRELATION OF CYTOKINE AND EFFECTOR MOLECULE 
PRODUCTION WITH HEMATOLOGICAL OUTCOMES 
Plasma cytokine and transcript cytokine levels were compared to Hb and Hct to 
determine if there was a correlation between pro- and anti-inflammatory cytokine production and 
transcription as predictors of anemia.  In the acute infection, plasma IL-10/TNF-α decreased in 
each animal by at least 40% (and up to>2,000%) in all four animals from peak parasitemia to the 
timepoint when the animal had the lowest Hb.  A low IL-10/TNF-α ratio has been shown to be 
associated with decrease in Hb in malarial anemia (55), (56), (29), (57).  
A low IL-10/TNF-α ratio at thrombocytopenia was significantly associated with the 
magnitude of PLT increase at parasite clearance (p<0.01).  Though high levels of PLT 
production during parasitemia have been correlated with disease severity (106), it appears that 
PLT production later in the infection as parasitemia is resolving, is beneficial.  Animals that had 
decreased Hb during the acute infection, showed elevated IL-12 plasma levels with higher levels 
of parasitemia.  In acute malaria, the suppression of bone marrow is partly in response to a 
decrease in EPO (90), which is downregulated by pro-inflammatory cytokines.  As well, non-
immune individuals have suppression of erythropoiesis in acute malaria (119), which could be 
due to overproduction of TNF-α (93).  We found that plasma levels of TNF-α on day 7 PI are 
positive predictors of anemia in acute malarial infection.  The ability to produce high levels of 
NO during acute malaria was significantly associated with high PLT levels at parasite clearance. 
Production of high plasma levels of NO at peak parasitemia were significantly correlated with 
high PLT at parasite clearance.  iNOS, expressed by primarily MO, has been shown to be 
protective during malaria, and has also been shown to be expressed by platelets (64).  NO also 
plays a critical role in the adhesion of pRBC, MO, LY and PLT to the endothelial wall in CM, 
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leading to enhanced disease severity (153).     Increased plasma NO during high parasitemia was 
associated with a thrombocytopenia, and high rebound in platelets at parasite clearance. 
Elimination of intracellular pathogens requires cell-mediated immunity generated by pro-
inflammatory molecules such as IL-12 (154).  Induction of immunity in susceptible A/J mice 
following administration of recombinant (r) IL-12 strongly supports the necessity of a Th1 
cytokine response for controlling a malarial infection (31).  Protection against the blood stage of 
murine P. chabaudi and P. berghei requires upregulation of IFN-γ and TNF-α, cytokines that 
presumably promote anti-parasitic properties through the generation of high levels of NO (31), 
(155).  In addition, administration of rIL-12 before inoculation of mice with P. yoelii or rhesus 
monkeys with P. cynomolgi provided 100% protection in both animal models of malaria through 
an IFN-γ-dependent (and perhaps NO-dependent) anti-plasmodial mechanism (32), (142).  
Enhanced IFN-γ,-responsiveness to malarial antigens has been associated with protection from 
severe malaria (152).  Taken together, previous studies in experimental malaria suggest that 
protective immunity in malaria requires a cascade of events that involve increased production of 
IL-12, IFN-γ, TNF-α, and NO. The balance between Th1 and Th2 cytokines is an essential 
component in the development of severe malaria.  This study demonstrated that high IL-10/ IL-
12, IFN-γ, TNF-α, and NO ratios were associated with increased parasite burden, whereas low 
IL-10/pro-inflammatory ratios were associated with decreased hemoglobin.   
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6.0  CONCLUSIONS AND FUTURE DIRECTIONS 
6.1 CONCLUSIONS 
In conclusion, we have found that both cytokine profiles and hematological parameters in 
rhesus macaques infected with P. coatneyi show many similarities to falciparum malarial anemia 
in humans.  Rhesus macaques develop malaria-induced anemia and thrombocytopenia when 
infected with P. coatneyi-.  If the animals are minimally treated during the acute infection, 
allowing for the controlled persistence of the parasite, but preventing CM, they can develop a 
more severe and persistent anemia than in the acute phase of disease.  Therefore, the primate 
model could be used for investigation of molecular- and mechanistic-based immunologic studies 
for vaccine and pharmacologic trials.  However, as in humans, there is considerable variation in 
levels of responses in macaques, so a larger sample size would be required to confer statistical 
significance.   
6.2 FUTURE DIRECTIONS 
 Future studies of the model should include examining profiles of rhesus macaques infected 
with P. coatneyi over a long-term chronic infection, and examining inflammatory mediators of 
disease severity (cytokine and effector molecules) at different time intervals during a 
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longitudinal chronic malarial anemia study.  Also, it would be interesting to look at in vitro 
studies taking cells from monkeys infected with P. coatneyi, and determining cytokine profiles.  
Likewise it would be advantageous to compare those results with in vitro stimulation of non-
infected, malaria-naïve rhesus macaques with parasite antigen and malarial pigment and 
determine levels of cytokine production.    
 Since malaria immunity requires both a humoral and cellular response, it would be 
beneficial to examine both the anti-parasite and parasite antigen antibody response during first a 
primary, then secondary P. coatneyi malarial infection in relation to cytokine production.    
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